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Abstract
Herpes simplex virus (HSV) entry into host cells requires the function of the viral envelope glycoprotein (g)
B in concert with three other envelope proteins, namely gD and the complex of gH/gL. Glycoprotein D
functions in receptor binding and communicates an activation signal to gB and/or to gH/gL to carry out
fusion between the viral envelope and cell membranes to release the capsid into the cell and begin the
replication process.
In this dissertation, I present a detailed mutagenic analysis of the putative HSV gB fusion loops. I mutated
each of the fourteen amino acids that comprise the two loops. In a space filling model of the gB structure, it is
apparent that the loops form a single structure, with a hydrophobic ridge at its center. This ridge is comprised
of several aromatic and hydrophobic amino acids and is surrounded almost exclusively by charged residues.
First, I mutated many of the residues that comprise the hydrophobic ridge. I discovered that five hydrophobic
amino acids, four from one loop and one from the other are critical for gB function as mutations to any one of
them impair fusion. Four of these comprise the hydrophobic ridge. To my surprise, I also discovered that two
charged residues that lie outside the hydrophobic ridge are also important for gB function. Their positions
suggest they may support insertion of the hydrophobic ridge into target membranes. These results support my
hypothesis that the two loops are an important functional domain that operate cooperatively as one structure.
I expressed several of the point mutants as soluble recombinant gB proteins, and characterized them in several
functional assays. I found that mutations of aromatic amino acids to charged ones or charged amino acids to
alanines abolished the ability of gB to associate with model liposome membranes. This provides good
evidence that these loops are fusion loops that function by inserting into a target membrane. Also, these
results suggest that aromatic and charged residues play important roles in target membrane insertion. Other
studies have shown that soluble gB can block virus entry, evidence that it interacts with its own entry receptor.
A recent report identified a cell surface protein, PILRα, that may fulfill this role. I found that the mutant forms
of gB blocked virus entry of virus as efficiently as WT gB, suggesting that the receptor binding region of gB is
distinct from the fusion loops. In contrast, these same mutants were significantly impaired in their ability to
bind to cells. I suggest that this apparent anomaly may be explained by the possibility that a proportion of gB
binds to a surface lipid via the fusion loops. Recently, our lab showed gB and gH/gL interact when triggered
for fusion by the addition of soluble gD. In collaboration with another lab member, we show that mutations to
the gB fusion loops abrogate gB association with gH/gL.
In summary, my results support the concept that gB functions as a fusion protein and that its two fusion loops
act in much the same way as do the fusion loops of VSV G or the class II fusion proteins. Five hydrophobic
and two charged residues are most important in the function of the gB fusion loops. I propose that loss of
target membrane insertion, impairment of cell binding, and abrogation of gB-gH/gL interaction are all
possible mechanisms by which mutations to the gB fusion loops inhibit gB dependent fusion. The remaining
enigma is why gB cannot carry out fusion on its own but must act in concert with gH/gL. Future studies may
provide the answer to that question. (Abstract shortened by UMI.)
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ABSTRACT 
HSV Glycoprotein B Fusion Loop Architecture and Mechanisms 
of Fusion Inhibition 
By Brian Hannah 
Thesis Advisors: Gary H. Cohen and Roselyn J. Eisenberg 
Herpes simplex virus (HSV) entry into host cells requires the function of the viral 
envelope glycoprotein (g) B in concert with three other envelope proteins, namely gD and 
the complex of gH/gL. Glycoprotein D functions in receptor binding and communicates 
an activation signal to gB and/or to gH/gL to carry out fusion between the viral envelope 
and cell membranes to release the capsid into the cell and begin the replication process. 
A variety of studies have attested to the importance of gH/gL in fusion, although the 
mechanism by which it functions is still somewhat mysterious. In contrast, a major 
contribution to our understanding of gB's role was recently provided by solution of its 
crystal structure. This structure revealed that gB has many functions that are 
characteristic of well known fusion proteins. Interestingly, gB has many structural 
features that bear striking similarity to ones of the surface glycoprotein (G) of vesicular 
stomatitis virus (VSV). Because G is the only surface glycoprotein of this enveloped 
virus, it is clearly the fusion protein of VSV. Both VSV G and HSV gB have features in 
common with the two known classes of fusion proteins (class I and class II). Like Class I 
fusion proteins, both G and gB are trimeric and have a central a-helical coiled-coil. In 
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contrast to the fusion peptides of class I proteins, G has two discontinuous fusion loops 
that are similar to the fusion loop of the class II proteins. HSV gB has two loops that are 
strikingly similar to the fusion loops of VSV G. The goal of my dissertation work has 
been to prove that these loops are the functional fusion loops of gB, to define the 
functional architecture of these loops, and to propose mechanisms for the inhibition of gB 
dependent fusion conferred by fusion loop mutants. 
In this dissertation, I present a detailed mutagenic analysis of the putative HSV 
gB fusion loops. I mutated each of the fourteen amino acids that comprise the two loops. 
In a space filling model of the gB structure, it is apparent that the loops form a single 
structure, with a hydrophobic ridge at its center. This ridge is comprised of several 
aromatic and hydrophobic amino acids and is surrounded almost exclusively by charged 
residues. First, I mutated many of the residues that comprise the hydrophobic ridge. I 
discovered that five hydrophobic amino acids, four from one loop and one from the other 
are critical for gB function as mutations to any one of them impair fusion. Four of these 
comprise the hydrophobic ridge. To my surprise, I also discovered that two charged 
residues that lie outside the hydrophobic ridge are also important for gB function. Their 
positions suggest they may support insertion of the hydrophobic ridge into target 
membranes. These results support my hypothesis that the two loops are an important 
functional domain that operate cooperatively as one structure. 
I expressed several of the point mutants as soluble recombinant gB proteins, and 
characterized them in several functional assays. I found that mutations of aromatic amino 
acids to charged ones or charged amino acids to alanines abolished the ability of gB to 
associate with model liposome membranes. This provides good evidence that these loops 
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are fusion loops that function by inserting into a target membrane. Also, these results 
suggest that aromatic and charged residues play important roles in target membrane 
insertion. Other studies have shown that soluble gB can block virus entry, evidence that 
it interacts with its own entry receptor. A recent report identified a cell surface protein, 
PELRa, that may fulfill this role. I found that the mutant forms of gB blocked virus entry 
of virus as efficiently as WT gB, suggesting that the receptor binding region of gB is 
distinct from the fusion loops. In contrast, these same mutants were significantly 
impaired in their ability to bind to cells. I suggest that this apparent anomaly may be 
explained by the possibility that a proportion of gB binds to a surface lipid via the fusion 
loops. Recently, our lab showed gB and gH/gL interact when triggered for fusion by the 
addition of soluble gD. In collaboration with another lab member, we show that 
mutations to the gB fusion loops abrogate gB association with gH/gL. 
In summary, my results support the concept that gB functions as a fusion protein 
and that its two fusion loops act in much the same way as do the fusion loops of VSV G 
or the class II fusion proteins. Five hydrophobic and two charged residues are most 
important in the function of the gB fusion loops. I propose that loss of target membrane 
insertion, impairment of cell binding, and abrogation of gB-gH/gL interaction are all 
possible mechanisms by which mutations to the gB fusion loops inhibit gB dependent 
fusion. The remaining enigma is why gB cannot carry out fusion on its own but must act 
in concert with gH/gL. Future studies may provide the answer to that question 
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I. INTRODUCTION 
A. HERPES SIMPLEX VIRUS 
1. Overview 
The family Herpesviridae is one of the largest virus families; its members infect 
nearly every vertebrate species from fish to mammals (148). Traditionally, membership 
in the family was based on architecture of the virion. However, all are known to share 
four significant biological properties: their genomes specify a large number of proteins, 
the synthesis of viral nucleic acids and capsid assembly occur in the nucleus, production 
of progeny virions is always accompanied by the destruction of the host cell, and all 
establish latency (148). The family has been divided into three subfamilies (a, P, and y), 
based on tropism and genomic organization. The a-herpesviruses were classified based 
on their wide host-cell range, short reproductive cycle, and rapid spread in culture. The 
P-herpesvirues have a more restricted host-cell range, longer reproductive cycle, and slow 
spread in culture. The y-herpesviruses are usually specific for either B or T lymphocytes. 
More recently, nucleotide sequence analysis has supported and further assisted this 
classification system. 
Herpesvirus infections are ubiquitous among the human population, and there are 
eight distinct human herpesviruses. This group includes 3 a-herpesviruses: herpes 
simplex types 1 and 2 (HSV-l/HSV-2) and the varicella zoster Virus (VZV), three p-
herpesviruses: cytomegalovirus (CMV), human herpesvirus 6 (HHV6) and Human 
herpesvirus 7 (HHV7) and two y-herpesviruses: Epstein Barr Virus (EBV) and Human 
herpesvirus 8 (HHV8). Approximately 80% of the adult population in the U.S. is 
seropositive for HSV -1 or -2 (189). These viruses most commonly cause recurrent oral 
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cold sores and genital lesions. Occasionally, HSV-2 viruses cause generalized neonatal 
infections. HSV-1 can cause keratitis and it is the leading infectious cause of blindness. 
Both can cause life-threatening complications in immunosuppressed individuals. VZV is 
the causative agent of chicken pox in children and shingles in older adults. Primary 
infections by a-herpesviruses typically result in epithelial lesions and spread to the 
peripheral nervous system where they establish life-long latency. Reactivation, usually 
due to stress, can lead to a recurrent "cold sore." 
2. Virion Structure 
The HSV virion is comprised of four separate compartments (Fig. 1) (70). The 
icosahedral capsid is constructed from four proteins, a characteristic of all herpesviruses. 
The capsid has been resolved in fine detail by electron microscopy studies (78,194). 
VP5, the major capsid protein, oligomerizes to form ring-shaped capsomers (14). The 
capsid has 150 hexon capsomers and 12 pentons. DNA is mechanically loaded into the 
capsid through a specialized penton capsomer at the apex of the capsid (126,127). The 
capsid also contains 320 triagonal trimers, each composed of one VP19c molecule and 
two VP23 molecules. VP26 is the fourth protein; it attaches to the tips of VP5 hexons 
(39,186). 
Inside the capsid, the linear double-stranded DNA genome is 152 kilobase (kb) 
pairs in length (113,152). The genome encodes at least 70 polypeptides and has a G + C 
content of about 68%. It consists of two covalently linked components, called the unique 
L (long) and unique S (short), each flanked by inverted repeat sequences. These repeats 
have important roles in the rolling circle mechanism of DNA replication. They allow the 
unique segments to be inverted relative to one another to form a circular unit (12). 
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Figure 1. Herpes simplex virus structure: Cryo-electron tomograph. 
Cutaway view of the virion interior, showing the capsid (light blue) and 
the tegument "cap"(orange) inside the envelope (blue and yellow), pp, 
proximal pole; dp, distal pole. Scale bar, 100 nm. 
Adapted from Grunewald etai, 2003. 
Surrounding the capsid is a less ordered protein layer called the tegument (194). 
This structure was long considered to be amorphous, but recent studies have revealed that 
it has a more ordered structure (70). Although the tegument is often asymmetrical, its 
inherent organization is suggested by the presence of tegument attachment sites on the 
capsid and cytoplasmic domains of viral membrane glycoproteins (11, 34, 51,132). 
Evidence suggests that immediately upon entry, tegument proteins are delivered to the 
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cytoplasm to augment the cellular environment for HSV infection (116). At least a dozen 
tegument proteins are released, and these include essential transcription factors such as 
VP16, viral kinases like Us3, and the Virion Host Shut-off (vhs) protein that facilitates 
mRNA degradation that results in premature arrest of host polypeptide synthesis. 
The viral membrane is the outermost layer of the virion. This host derived lipid 
bilayer most likely has its origins in the trans-golgi network. It is studded with at least 11 
viral glycoproteins, five of which are involved in entry, while the others have a variety of 
functions ranging from immune evasion (56) to facilitating cell to cell spread (86). 
3. Virus life-cycle 
Transmission of HSV usually occurs through a primary infection at the mucus 
membranes resulting in a primary lesion (86). The virus then spreads through cell-cell 
contacts, infects sensory neurons that innervate the region and travel up the neurons in a 
retrograde direction until it reaches the trigeminal ganglion where it establishes a latent 
infection, during which no virus is produced (87). The virus can be periodically re-
activated to travel back down the sensory neurons in the anterograde direction and cause 
secondary lesions by replicating in epithelial cells and keratinocytes that are often near 
the site of initial infection (42). Thus, within its normal life cycle, the virus must infect 
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Figure 2. Herpes simplex virus life cycle. HSV attaches to the cell surface and 
either fuses at the plasma membrane or it is endocytosed and fuses with the 
endocytic vesicle. The capsid travels along microtubules and docks at the nuclear 
pore where it injects the dsDNA genome into the nucleus. Transcription of viral 
genes occurs in a highly ordered process. Capsids are assembled and packed with 
the viral genome in the nucleus. Mature capsids exit the nucleus, become 
tegumented and aquire their final envelope in the golgi apparatus. Mature virions 
are released, often resulting in host cell death. 
Adapted from http://upload.wikimedia.Org/wikipedia/en/3/35/HSV_replication.png 
multiple cell types. Accordingly, the virus exhibits a wide tissue tropism that is reflected 
by the wide variety of cells it can infect in cell culture. The herpesvirus life cycle is 
summarized in Figure 2. 
HSV attachment and entry is mediated by five surface glycoproteins. After 
attachment, the virus either fuses at the cellular membrane or is endocytosed and fuses 
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with the endocytic vesicle to release the capsid into the cytoplasm (75). This process is 
discussed in greater detail below (IB). The capsid is then transported to the nuclear 
membrane by microtubule-based transport and subsequently docks at the nuclear pore 
(43, 161, 163). The genome enters the nucleus where it circularizes to form an episome 
and localizes to intranuclear sites near ND10 structures (18, 50,112). 
Transcription of viral gene products proceeds in a highly ordered cascade fashion, 
facilitated primarily by the host RNA polymerase II. The genes have been classified into 
three temporal groups, a, p, & y (86). The tegument proteins that are delivered upon 
entry, including VP16, alter the cellular environment (prior to viral protein synthesis) to 
allow transcription of the six Immediate early (IE) or a genes, around 2 to 4 hours post-
infection (hpi) (25). The six proteins are: ICPO, ICP4, ICP22, ICP27, ICP47, and Usl.5, 
five of which stimulate p, or early (E), gene synthesis (86). P-gene transcription peaks at 
4 to 8 hpi. The expressed proteins include thymidine kinase, DNA polymerase and many 
others that promote viral DNA synthesis and y-gene expression. The P-genes have been 
separated into two groups, pi-genes and P2 genes. The pi-genes are expressed almost 
concurrently with the synthesis of proteins encoded by the a-genes. The p2-genes are 
expressed with more delay, and some require ICP27 for their expression. 
The y-genes are the last group of genes to be expressed. They include viral 
structural proteins and have been separated into yl-genes (also called leaky-late) and y2-
genes based on their expression profile. The leaky-late genes, which include gB, gD, and 
ICP5 among others, are expressed to a limited extent at early times in infection and 
increase several fold during viral DNA replication. The y2-genes are only expressed late 
in infection, after viral DNA replication has commenced (86). 
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HSV DNA replication can be detected as early as 2 to 4h p.i. and requires several 
viral enzymes and DNA binding proteins (187). The genome contains three origins of 
replication, each of which is individually sufficient to mediate genome replication. As 
viral DNA synthesis progresses, the progeny DNA molecules and replication complexes 
accumulate in globular structures within the nucleus called replication compartments. 
Viral DNA replication proceeds within these areas via a rolling circle mechanism to yield 
head-to-tail concatemers, which are cleaved into monomeric genomes that are packaged 
into preassembled capsids (12, 78). 
Historically, the mechanism of HSV egress has been a subject of controversy and 
even the most widely accepted models are still being contested. Currently, the most 
popular model proposes a complex process of envelopment and tegumentation known as 
the envelopment/re-envelopment model (48,116, 160,183). In this model capsids 
initially bud through the inner nuclear membrane, gaining a primary envelope from that 
structure. In support of this, deletion of particular viral genes leads to accumulation of 
capsids (with a single membrane) in the peri-nuclear space (52,122,131). Capsids then 
fuse with the outer nuclear membrane, in a de-envelopment step, to release naked capsids 
into the cytoplasm. This model is consistent with the localization of several viral 
glycoproteins to the nuclear membrane as well as to the golgi and plasma membranes (5). 
Recent studies suggest that gB and gH/gL function redundantly in primary fusion, 
because this step is completely blocked only when both are absent (52). Final 
envelopment, or re-envelopment, occurs within the trans-Golgi network and final 
tegumentation occurs at some time and place between the de-envelopment and re-
envelopment steps. 
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All herpesviruses establish latent infections. HSV latently infects the subset of 
neurons of the trigeminal ganglion that innervate the site of the primary infection. In 
these latently infected cells, the HSV genome exists as an extrachromosomal episome 
and gene expression is largely silenced (41,115,138,147). The only detectable viral 
transcript is the Latency Associated Transcript (LAT), a stable intron for which no 
translatable products have been identified (54, 138). HSV can periodically reactivate and 
travel by anterograde axonal transport back to the site of primary infection to cause 
recurrent lesions. The mechanism of reactivation is poorly understood, but it can be 
triggered by stress at the organismal and cellular level (86). 
A. HERPES SIMPLEX VIRUS ENTRY 
For many years, the paradigm for HSV entry was that it occurred only at the 
plasma membrane. Vero cells were the cell line of choice for these studies. Recently, it 
was reported that Vero cells were likely the exception to the rule (129); HSV virions 
enter most cells by endocytosis and subsequent fusion at the endocytic membrane in 
either a pH dependent or independent manner (75, 119, 128, 129). The choice of entry 
pathway appears to be cell-type specific, but some studies using mutant viruses suggest 
that there is some viral specificity as well (38). It is clear that much remains to be 
discovered about HSV entry pathways. 
Although HSV has eleven or more glycoproteins in its envelope, experiments 
with viruses lacking the gene for any individual glycoproteins have shown that only four 
are essential for entry regardless of the pathway exploited. Glycoproteins gB, gD, and 
the gH/gL make up the entry complex of HSV; they are necessary and sufficient for HSV 
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entry into all target cells that express a gD receptor (19, 53,75,149,166). Several 
antibodies raised against HSV gB, gD, and gH have virus neutralizing and cell-cell fusion 
neutralizing ability (31,47, 61, 134). 
In addition, expression of these four proteins in cells neighboring those that 
express a gD receptor is sufficient for cell-cell fusion (16,123). Attachment of gC to 
heparan sulfate proteoglycans (HSPG) is an important initial steps in entry that brings the 
virus in close association with the cell (Fig. 2) (24,173). However, mutants lacking the 
gC gene are still infectious and the virus can infect cells deficient in HSPG (6,155). 
Moreover, this function is redundant e.g. HSV-2 gB binds heparan sulfate with greater 
affinity than HSV-2 gC (30). Of the herpesvirus glycoproteins involved in entry, gB is 
the most conserved. Together, gB and gH/gL are the core fusion components for all 
herpesviruses (166). 
The current model for HSV entry into cells (Fig. 3) is that initial attachment of 
virus to cells occurs through the interaction of gC and gB with cell surface 
glycosaminoglycans, heparan or chondroitin sulfate (155). The next step is engagement 
of gD with one of three cellular receptors (75, 81, 141, 164). The receptors belong to 
three classes. HVEM belongs to the tumor necrosis factor receptor family, nectin-1 
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1. Attachment 2. Receptor binding (activation) 
Figure 3. Illustration of steps during HSV entry. 1. gB and gC 
facilitate the initial attachment through interaction with HSPG on the cell 
surface. 2. gD then engages one of three cell surface receptors and 
undergoes a conformational change that opens up the structure, 
displacing the C-terminus, in red, and allowing the "pro-fusion" domain, 
loop in red, to communicate an activation signal to gB and/or gH/gL 
which function to complete fusion. 
belongs to the immunoglobulin family, and 3-OS-HS is a specifically modified form of 
heparan sulfate (165,166). 
Several structural studies have shed much light on the conformational changes 
that occur in gD as a consequence of receptor binding (26, 89,179). A current model 
postulates that native gD is in a closed conformation with the C-terminus in close 
proximity to the receptor binding sites. When gD engages one of its receptors, it 
undergoes a conformational change that opens up the structure and displaces the C-
terminus allowing the "pro-fusion" domain to communicate a signal to gB and/or gH/gL 
via protein-protein interactions (75,90). Earlier studies showed that the glycoproteins are 
within 11 A of one another and that their associations change as entry proceeds (71). But 
no stable interaction was shown until 2007, when both gD-gB and gB-gH/gL were shown 
to associate through the use of bi-molecular complementation (2,3). Importantly gB and 
10 
gH/gL stably interact with one another only after gD engages its receptor and fusion 
occurs. 
The gD-receptor interactions are well understood, but the subsequent steps 
leading to fusion are still mysterious. There is much early evidence that gB is the viral 
fusogen. Syncytial and rate-of-entry (roe) mutations have been mapped to both the 
cytoplasmic domain and the ectodomain of gB (57, 69,77,192). Most herpesvirus gBs 
cannot function in the absence of gH/gL, but a gB mutant of EBV exhibits increased 
surface expression and can cause cells to fuse in the absence of other viral proteins (114). 
Many viruses exploit lipid rafts, plasma membrane microdomains enriched in cholesterol, 
for cellular entry. Influenza HA and parainfluenza virus F bind lipid rafts, and the 
receptors for HIV and murine leukemia virus are found in lipid rafts (106,108,175). 
Among the five entry glycoproteins of HSV only gB associates with lipid rafts (9). 
Similarly to influenza HA, this interaction is cholesterol dependent. There is evidence 
gB binds a cell surface receptor (8) and a recent report has proposed that paired 
immunoglobulin-like type 2 receptor (PILR)a (153) is the gB receptor. Importantly, gB 
has features typical of a fusion protein as shown by its crystal structure (76)(to be 
described below). 
There is also evidence that gH/gL can act as a fusogen (23). First, the absence of 
or mutations to gH/gL abrogate fusion (40). Second, gH is predicted to have two heptad 
repeats, structural motifs common to fusion proteins (to be discussed IC)(65). Peptides 
derived from these motifs have some properties of a viral fusion protein (64, 66). 
However, evidence supporting these reports has been limited. 
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gB is structurally homologous to the sole surface glycoprotein (G) of vesicular 
stomatitis virus, a commonly studied rhabdovirus (32, 33, 37, 76, 145). Both G and gB 
have structural features that are commonly seen in either class I or class II fusion 
proteins. Because of this, they are considered to be members of a third class (class III) of 
fusion protein (169). It now seems clear that gB is the HSV fusogen, but it is also clear 
that gH/gL plays an essential role in fusion as gB does not normally function on its own. 
What is this function? And if HSV gB is so much like VSV G, why does it required 
gH/gL to function? It is clear that many questions remain as to what role this 
heterodimer plays in HSV entry. 
B. FUSION PROTEINS 
1. Class I Fusion Proteins 
Influenza HA, the prototypical viral fusion protein, was first crystallized in 1981 
(177,184). This advance virtually pioneered structural virology; for the first time, there 
was a structure to guide hypotheses and experiments to learn how viruses enter cells by 
membrane fusion. The native HA type 1 transmembrane protein, anchored in the viral 
membrane at its C-terminus, is a 220 kDa elongated homotrimer. Each protomer consists 
of two disulfide linked subunits, HAi and HA2, that are derived from the precursor HA0 
by proteolytic cleavage. HAi is 328 residues, forms the majority of a globular head 
structure located at the viral distal tip of the protein, and contains the receptor binding 
domain (159). HA2 is 221 residues, contains the transmembrane domain, forms the 
majority of a long central a-helical region, and contains the major fusion components of 
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the protein (177,184). This division of receptor binding in one polypeptide and fusion 
activity in a second polypeptide is a hallmark of class I fusion proteins (Fig. 4). 
Influenza Virus HA 
Paramyxovirus F 
'
mmfm 
F2 
HA1 
FP HR1 
-S-S — 
-S-S 
F1 
FP 
I 
HA2 
JUBl_^lHR2 TM 
HR2 TM 
B Paramyxovirus F Influenza HA 
Figure 4. Class I Fusion Proteins. A) Linear schematic of Influenza HA and 
Paramyxovirus F proteins. Class I fusion proteins are proteolytically cleaved to 
produce two subunits. The C-terminal subunit contains the fusogenic function. 
HR1 and HR2 fold back on each other to form a 6HB. B) Crystal structures of 
paramyxovirus F° and Influenza HAatlowpH. C) Cryo-EM tomograph of the SARS 
virus, the spike (S) protein is in orange. Like SARS S, class I fusion proteins are 
visualized as spikes on the surface of the virion. (C) Adapted from From Beniac 
et al. 2006. 
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Initially, the authors were perplexed by the structure of the HA trimer because its 
135A length seemed to preclude movement of the viral and cellular membranes into the 
same space (184). The hydrophobic fusion peptide of HA2 was 100A away from the 
distal tip of the molecule, 35A from the viral membrane, and buried in the interior of the 
molecule (63,158). Thus, insertion of this peptide into the target membrane should be 
physically impossible. Two major clues in solving this mystery were data suggesting that 
influenza virus is endocytosed and fuses in a pH-dependent manner, and that HA 
undergoes conformational changes at the pH of fusion (44). When HA was crystallized 
at this lower pH, its structure was dramatically altered. The protein was refolded around 
the central a-helix, which remained largely unchanged. Relocation of the N-terminus 
100 A toward the target membrane, could move the now exposed fusion peptide (short 
hydrophobic alpha-helix) 150 A or more (17). Solution of HA in different conformations 
guided a fundamental understanding of how enveloped viruses achieve membrane fusion. 
Many of the lessons learned from HA apply to glycoproteins from many other enveloped 
viruses that are structurally homologous and use very similar mechanisms in fusion (35). 
These class I members include the fusion protein of paramyxoviruses, 
retroviruses, orthomyxoviruses, filoviruses, arenaviruses (58), and coronaviruses (13) 
(Fig. 4). As mentioned above, these proteins are proteolytically cleaved in the later steps 
of maturation to become fusogenically active. They are trimers in their pre- and post-
fusion forms and their most recognizable feature is a long central a-helix. If the protein 
has receptor binding function, the region responsible for this interaction is located in the 
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N-terminal subunit. The C-terminal subunit of these proteins contains the fusogenic 
function, driven largely by the HRi and HR2 regions, which are short for heptad repeat 1 
and 2. HRi is often the central a-helix. During fusion HR2, also often a-helical, folds 
back onto HRi to form a "trimer of hairpins" configuration that is often in the form of a 
6-helix bundle (6HB) (Fig. 4) (35). The proteins are visualized as spikes on the surface 
of a virion (10). Before fusion, class I fusion proteins are folded into a high energy 
metastable conformation. A trigger e.g. receptor binding and/or low pH provides the 
necessary activation energy for the protein to refold into a lower energy and more stable 
conformation. In this way, class I fusion proteins have been likened to a spring, loaded 
with the potential energy needed to drive fusion (29). 
2. Class II Fusion Proteins 
The class II fusion proteins are considerably less well understood than their class I 
counterparts (Fig. 5) (74). Semliki forest virus (SFV, an alphaviras) El and Tick-borne 
encephalitis virus (TBEV, a flaviviras) E protein share no primary sequence homology, 
but their 3D protein structures are very similar elongated finger like molecules (83) (Fig. 
5A). These proteins are expressed as polyproteins, cleaved, and folded co-translationaily 
with an accessory protein (100,191). Flavivirus E is synthesized with the prM protein, 
which is cleaved to produce the M transmembrane protein (73). Post-budding 
modifications remove much of the M protein, producing El homodimers that lie flat on 
the surface of the virus in a "herringbone" pattern at neutral pH (Fig. 5B) (142). 
Alphaviras E is synthesized with the premature p62 protein, which is cleaved to produce 
the E2 transmembrane protein. These two membrane bound glycoproteins cover the 
surface of the virion in a T=4 icosahedral symmetry, with El lying flat on the surface 
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forming an icosahdral scaffold and E2 forming protruding spikes (Fig. 5C). E2 
associates tightly with the E fusion peptide, an internal loop, and is responsible for 
A l 38 FP BO 169 SFVE1 E 3 II K g — 273, 291 
1 48 FP 138 191 286 301 
TBE E izsza 11 cs^za g a g 
J 8 1 4 1 3 4 J 8 
395 449 496 
B (cacsptor binding) (receptor binding and " membrane-'fusion). -
(membrane fusion) 
•:S50A 
D 
Figure 5. Class II fusion proteins. A) Schematic of the alphavirus E1 and flavivirus 
E proteins. Domain I is in red, domain II is in yellow, and domain III is in blue. B) Pre-
fusion crystal structure of alphavirus E1/E2 heterodimer (E2 as spheres) and 
flavivirus E/E homodimers. Arrows point to the fusion loop of each protein. C) 
Alphavirus virion, showing the E1 icosahdral latice (left) and E2 spikes (right). D) Post-
fusion crystal structure of E1 and E homotrimers. One protomer is colored to match 
A), B), and C) which are adapted from Kielien and Rey 2006. 
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receptor binding and blocking E interactions at the trimer interface (98). These structures 
are very different from the class I fusion proteins (85). At neutral pH, they lie flat on the 
virion as dimers compared to the trimeric spikes of class I proteins. Class II proteins are 
not cleaved as are class I proteins, but instead are activated by cleavage of their accessory 
proteins. The class II proteins are composed almost entirely of P-sheets, with little a-
helical content, and their fusion peptide is an internal loop that is buried at the dimer 
interface. 
When the class II proteins were crystallized at low pH, their 3D structure was 
converted from the flat dimer to an elongated trimeric spike (Fig. 5D) (15, 67, 68). There 
is little refolding of the protein. Most of the rearrangements are in the tertiary 
organization of the protein as opposed to the large conformational changes seen in class I 
proteins. In fact, the low pH structures of these proteins are thought to be very similar to 
their post-fusion structures. It is thought that exposure to a low pH (likely after receptor 
binding, but within an endosome) causes dimer dissociation which allows the protein to 
"flip up" and interact with a membrane in a short-lived monomeric structural 
intermediate. Trimer formation is necessary for fusion and the transition of monomers 
into hairpin configuration trimers likely drives fusion (175,178). Once again, this 
process is very different from that of the class I fusion proteins. When compared with 
class I proteins, the most noticeable differences in structure are the lack of a distinct 
globular domain at the distal tip and the absence of an a-helical core. Instead of an 
external a-helical fusion peptide, as in class I fusion proteins, the class II fusion proteins 
have an internal fusion loop that serves as the fusion peptide. In the pre-fusion 
17 
conformations, class I proteins are seen as trimeric spikes on the virion but, as mentioned, 
class II proteins are seen as dimers that lie flat on the virion. However, in both cases, 
fusion is driven by conformational changes into trimeric hairpin structures (178). 
3. VSVG 
Vesicular stomatitis virus is a well studied bullet shaped rhabdovirus closely 
related to rabies virus (32, 33, 37). Rhabdoviruses have a RNA genome of negative 
polarity and infect a great variety of organisms. The virus enters cells via endocytosis 
and fusion between the viral membrane and the membrane of the endocytic vesicle 
occurs in a pH-dependent manner. On the viral surface is a single transmembrane 
glycoprotein (G) that mediates both cellular attachment and viral entry. Accordingly, it is 
the ligand of a still unidentified cell surface receptor (37, 60,171,188). 
VSV G is a 495 a.a. trimeric spike with 446 of those residues on the exterior of 
the virus (Fig 6A). The G protein adopts at least three conformations depending on pH: 
the native (above pH 7), the activated hydrophobic, and the post-fusion inactive protein. 
A equilibrium exists between the conformations that is shifted toward the post-fusion 
form at low pH (60). The post-fusion form is antigenically distinct from the first two 
(59). These conformational changes are reversible; thus, the protein is not in a metastable 
state (60). There are no a-helical heptad repeats as seen in class I fusion proteins. G has 
an internal fusion peptide (45, 55,102,170,193) that is more analogous to class II 
proteins (145). But, it is not proteolytically cleaved from any polyprotein precursor nor is 
it associated with another protein at any time during synthesis or maturation. Thus, it is 
thought that G represents a new class of viral fusion protein (37, 85). 
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VSV G has been crystallized and the structures of the pre- and post-fusion 
structures have been determined. The post-fusion structure of G is reminiscent of an 
'•!.:,» .a*;ti. »4«K W6 4S6 495 
B 
VSV 6 
(prefusion) 
VSVG 
{postfusion) 
Figure 6. Vesicular stomatitis G protein. A) Linear schematic G protein-
Domain I is in red, II in blue, III in orange, and IV in yellow. B) Ribbon diagrams of 
the Post- and C) pre-fusion crystal structures of G colored to match A). Domain I is 
the globular head. Domain II is the central a-helical core. Domain III is the "neck" 
region that has the fold of a PH domain. Domain IV is the elongated fusion domain 
that contains the fusion loops, in green. Most of the transition form the pre- to post-
fusion form can be explained by movements of the domains with respect to one 
another. Adapted from Roche et al. 2008. 
19 
inverted cone (Fig. 6B). It is an 125 A spike and its head (bottom in Fig. 6B) is 60 A in 
diameter (145). The organization of G is completely different from that of the class I and 
class II proteins. It consists of four domains. Domain I (red in Fig. 6B) is a globular 
head at bottom of the molecule and is composed of P-sheets. Domain II (blue) is 
comprised almost entirely of a central a-helical core that is reminiscent of the a-helical 
region of class I fusion proteins and is important in stabilizing the trimer. Domain III 
(orange) is referred to as a "neck" region that has the fold of a pleckstrin-homology (PH) 
domain (96, 97). Domain IV, in yellow, is an elongated fusion domain which contains 
two loops similar to the fusion loop of class II fusion proteins. Thus, unlike all other 
fusion proteins characterized to date, VSV G has features reminiscent of both class I and 
class II fusion proteins (145,169). However it is important to note that this form displays 
the classic hairpin (post-fusion) form of other viral fusion proteins, with the 
transmembrane and fusion domains at the same end of the molecule (85). Most 
importantly, with respect to this dissertation, the post-fusion form of G is structurally 
homologous to HSV gB, whose structure was solved at the same time (76,145,169). 
Upon first examination, the pre-fusion structure of G (Fig. 6C) appears to be very 
different from the post-fusion form (144-146). In the pre-fusion form, the protein is 88 A 
tall and resembles a tripod (Fig. 6C). Each leg of the tripod is composed of the fusion 
domain (DI), with the fusion loops presumably inserted into the viral membrane. In 
contrast to both class I and class II fusion proteins, the fusion peptide (not shown in Fig. 
4, green in Fig. 5D) are not buried at an oligomeric interface or in the interior of the 
protein (144, 146). The most C-terminal residues are packed against the fusion domain, 
suggesting that the transmembrane domains of each protomer are separated in the 
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membrane. Interestingly, both the pre- and post-fusion conformations have a 6HB at the 
center of the molecule. Like class I fusion proteins, much of the refolding from pre- to 
post- fusion occurs around this structural "anchor." The transition of G from pre- to post-
fusion involves dramatic changes in structure. But most of the transition can be 
explained by movements of the domains with respect to one another. The basic structure 
of the individual domains remains unchanged. This property is similar to the class II 
fusion proteins. But in contrast to the class II proteins, G does not change its oligomeric 
state. 
The G protein had been well studied prior to the solution of its structure (37). 
Purified phophatidylserine (PS) can block VSV binding to Vero cells (154). At low pH 
PS, GM3 ganglioside, and phosphatidlyinosital are able to block VSV binding to 
erythrocytes. Interestingly, analogs missing only the negatively charged groups of these 
molecules were tested, their ability to block was greatly reduced. Thus, it was concluded 
that G protein binding to negatively charged lipids is crucial in VSV G binding to cells 
(111). It is also important in G mediated fusion. When G protein is reconstituted into 
liposomes, the extent of pH-induced conformational changes depends on the number of 
negative charges in the target membrane. Additionally, G protein-mediated membrane 
fusion may be correlated with the PS content in the vesicles (27). Using various 
biochemical methods, it has been shown that at low pH, two histidine residues are 
protonated and this appears to be important in binding to cells and fusion (28). It has 
been suggested that G binds to a phospholipid domain in the cell surface membrane as an 
early step of the fusion process (190). Perhaps G binds a cell surface receptor during 
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attachment and then binds a different moiety in the endocytic vesicle after it undergoes a 
low pH dependent conformational change. This concept will be revisited below. 
Photolabeling experiments mapped the fusion domain of G to a.a. 59 to 221 (45). 
Subsequent mutational analysis pinpointed the importance of conserved Gly, Pro, or Asp 
residues located in the region between amino acids 117 to 137 (55). Substitution of 
conserved aromatic amino acids in this region abolished G dependent cell-cell fusion and 
virus entry (143,170). Finally, the crystal structure showed that this region is at the tips 
of the two putative fusion loops that are similar in structure and hydrophobicity to the 
fusion loop of class II fusion proteins (145). 
The structural homology of VS V G to HSV gB was unexpected. Until these 
structures were solved, the two viruses were thought to have nothing in common. gB has 
five structural domains, four of which are homologous to domains of G. The folds of 
these domains and the connectivity of the polypeptide are essentially the same (169). 
Some of the biochemical observations made for G have been observed with gB. Neither 
is expressed with an accessory protein, and neither are metastable; their pH dependent 
conformational changes are reversible (60) (unpublished data for gB). Although some 
herpesvirus gBs are cleaved, this cleavage has been shown to be unnecessary (88). 
Neither HSV gB nor VSV G are cleaved. Based on their structural and biochemical 
similarities, there is little doubt that these two proteins share an evolutionary origin (169). 
Thus, the body of G protein knowledge was a factor in guiding this study. 
4. Fusion Peptides and Fusion Loops 
The term fusion peptide has traditionally been used to refer to short, N-terminal 
hydrophobic a-helical peptide stretches rich in glycines and alanines that are used by 
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viral proteins to penetrate and anchor themselves in a target cellular membrane (174). 
Like every other aspect of the fusion proteins, this structural/functional feature is best 
understood in influenza HA. Class I fusion proteins are synthesized as one polypeptide 
chain, but are cleaved during the late steps of maturation to yield two disulfide linked 
subunits. The fusion peptide is the first twenty or so residues at the N-terminus of the C-
terminal fragment which is anchored into the viral envelope by the transmembrane 
domain. Exposure to a particular signal, most often low pH, triggers a conformational 
change in the protein that re-locates the fusion peptide to a position more optimal for 
membrane insertion. Class I fusion peptides are believed to interact with the target 
membrane in an oblique fashion (181). NMR studies of peptides in a membrane suggest 
that the HA fusion peptide adopts an a-helical "boomerang," or an inverted V structure 
upon insertion into the aliphatic core of the bilayer at low pH, with aromatic residues 
inserted most deeply and forming a hydrophobic core at the kink of the V. The charged 
residues interact with the phospholipids head groups and are unable to penetrate the 
hydrophobic core (91). Even though the above data were obtained using a soluble 
peptide, a similarly obtained depth profile using the full-length HA2 showed that the 
peptide inserts into the membrane 15 A beyond the phosphate group (107). 
The fusion loop, has been characterized more recently. Initially, the internal 
structures were defined as peptides stretches of 16-20 apolar amino acids bounded by 
charged amino acids residues (190). Early modeling suggested they were amphipathic 
helices with bulky apolar amino acids on one face of the helix (110, 181, 182). However, 
crystal structures show that they are loops that extend from P-sheets at the base of the 
post-fusion proteins (98, 120,142,145). These domains are masked at the dimer interface 
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in the pre-fusion forms of the class II fusion proteins. In the low pH structures they are 
exposed and located at the same end of the protein as the transmembrane domain, where 
the fusion pore would presumably be. Selective mutagenesis in SFV E, TBEV El and 
VSV G has identified these domains as important for fusion (1, 99, 170). In class II 
proteins, one loop serves this function. In class III proteins, two adjacent loops are 
postulated to cooperate in carrying out this function. Fusion loops are believed to 
function similarly to a classical fusion peptide; structural data suggests that fusion loops 
project their aromatic side chains into the aliphatic region of the outer leaflet of the target 
bilayer (15,120,144,145). Functional data using TBEV E and SFV El showed that 
substitutions in the fusion loops (hydrophobic amino acids to charged residues) inhibited 
liposome association (1, 84). Structurally, it is not difficult to visualize the similarities 
between the fusion loop and a classical fusion peptide in a membrane. The fusion loop 
can be imagined as a a "V" whereas the class I fusion peptide is an inverted "V." Most 
likely, both classes of fusion peptide do not traverse the bilayer, but penetrate only the 
aliphatic region of the outer membrane leaflet. 
The body of literature on fusion loop mutagenesis (mostly TBEV E, SFV El, and 
VSV G) was crucial in shaping my studies. The composition and function of the gB 
fusion loops are the primary focus of this dissertation and they are discussed at length 
below. 
5. Fusion Mechanisms 
Fusion is an energetically unfavorable process. Fusion proteins function in 
overcoming the repulsive hydration force that discourages fusion and/or by promoting the 
attractive forces that promote fusion (181). Thus, even though class I and II fusion 
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proteins are very different structurally, they must exploit the same principles to drive 
membrane fusion. Convergent evolution has led to diverse viral fusion machines that 
employ similar mechanisms in how they achieve membrane fusion. The similarity arises 
from the "spring loaded" nature of these proteins, and the general unfolding-refolding 
process they go through to release this stored energy (Figs. 7 & 8). 
As spring loaded machines, most fusion proteins exist in a relatively unstable 
state. It is thought that most are metastable. In their native (fusion active forms) they are 
high in potential energy (high enthalpy) and require external activation energy to trigger a 
series of conformational changes. These changes transform the protein into an unstable 
short-lived intermediate state and finally, into a stable post-fusion state (low enthalpy). 
This process converts the stored potential energy of the native fusion protein into 
mechanical energy used to drive fusion. The forces, or "fusion triggers," that initiate 
fusion can be low pH (found in the endosome), receptor binding, proteolytic cleavage, or 
some combination of these (46). 
Fusion complexes range from well-understood single protein machines (Influenza 
HA), to the poorly understood Entry-fusion complex of pox viruses (121, 162). Receptor 
binding is a common fusion trigger, that can occur either through an associated protein or 
the fusion protein itself. A good example of this is in paramyxoviruses which have two 
transmembrane proteins in their envelopes, HA and neuraminidase. Neuraminidase must 
first engage its receptor before F continues the process (92). Another example is Semliki 
forest virus, where E2 is the receptor binding protein and El is the fusogen (83). In 
influenza virus, HAi binds receptor and HA2 contains the fusion peptide that is exposed 
by the low pH of the endocytic vesicle. The SARS coronavirus takes this a step further. 
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The spike protein S binds receptor and undergoes a conformational change. Subsequent 
cleavage of S by cathepsin L (a pH sensitive protease located in the endosome) activates 
the protein (156). In all of these cases, it is thought that fusion activation causes the 
proteins to undergo a conformational change into a membrane interacting intermediate. 
Target membrane interaction sends a second trigger to the proteins, that causes them to 
fold into the lowest energy state i.e., the post-fusion form (46,175,178) Synchronized 
structural rearrangements of several molecules cooperatively generate enough membrane 
perturbation and energy to merge two the opposing membranes (85). 
Figure 7. Proposed Model for membrane fusion mediated by class I fusion 
proteins, a) The metastable conformation of a trimeric generalized fusion protein, with 
helical domain A in orange, helical domain B in pink, and the transmembrane domain 
in purple, a) After binding to a receptor on the cellular membrane, or on exposure to 
the low pH, the protein forms an extended conformation and the hydrophobic fusion 
peptide (red) inserts into the target membrane, c) Several trimers are thought to be 
involved, d) Protein refolding begins, causing the membranes to bend towards each 
other, e) Formation of a restricted hemifusion stalk allows the lipids in the outer 
leaflets of the membranes to mix. f) Protein refolding completes, forming the final 
hairpin structure. Only a and f have been observed by crystallography, but 
biochemical data support many of the proposed steps. Adapted from Jardetzky and 
Lamb 2004 
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Figure 8. Proposed Model for membrane fusion mediated by class II fusion 
proteins, illustrated for Semliki Forest virus, a) Native virions, showing E1 
coloured and E2 in light grey interacting with E1 and covering the fusion loop, b) 
Trigger 1: low pH triggers E1-E2 dissociation and exposure of the fusion loop, c) 
Trigger 2: low-pH- and cholesterol-dependent insertion of the fusion loop, leading to 
the alignment of E1 subunits parallel to each other, favouring trimerization. d) Fold-
back process: domain III and the stem region move towards the fusion loop. 
Cooperative interactions between trimers through their fusion loops distort the target 
membrane, e) Folding of the domain III, in yellow, and stem segments against the 
body of the trimer pulls transmembrane (TM) segments against each other, distorting 
the viral membrane, f) Opposing dome-like deformations in the two membraneslead to 
mixing of the outer leaflets (hemifusion). g) To reach the final stable conformation, the 
TM segments have to be closely juxtaposed to the fusion loop. This is only possible by 
opening an initial fusion pore. Adapted from Rey and Kielien 2006 
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The transition from a membrane interacting intermediate to a stable post-fusion structure 
involves a similar fold-back mechanism in all of the known fusion proteins. When they 
fold back on themselves, they form a hairpin to accomplish their job. Class I proteins use 
their two opposing a -helical domains; during the fold-back event (also called hairpin 
formation), to form a 6HB (85) (Fig. 7). Although class II proteins have little alpha 
helical content, they also fold back on themselves into a more stable hairpin structure 
(Fig. 8). 
Interestingly, VSV G [and HSV glycoprotein B], does not exist in a metastable 
state (60)(unpublished data for gB). Conformational changes triggered by low pH are 
reversible with back neutralization of the pH. Perhaps there is a smaller difference in 
enthalpy and a lower activation energy between the various conformations of G [and 
possibly gB] than for class I and II proteins. It is possibly that metastability is not always 
a requirement of fusion proteins. In the future, it will be interesting to understand what 
makes G [and possibly gB] competent to complete fusion. 
D. GLYCOPROTEIN B 
/ . gB Genetic Structure 
The ORF for gB encodes a 934 residue polypeptide; the 30 a. a. signal sequence is 
proteolytically cleaved during maturation (Fig 9A). The gB ectodomain is 697 a.a. with a 
68 a.a. transmembrane domain and al09 a.a. cytoplasmic tail. It has three hydrophobic 
domains, between a.a. 727 and 795 the third of which is the transmembrane anchor. 
Deletion of this third region yields a soluble protein (140). The role of the first two 
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hydrophobic domains is unknown, but single substitutions of several conserved glycines 
Figure 9. Crystal Structure of HSV Glycoprotein B. A) Domain architecture 
of gB. Domains observed in the crystal structure are highlighted in different 
colors, and their corresponding first residue positions are shown. B) Ribbon 
diagram of a single gB protomer. The domains are rendered in colors 
corresponding to A). Labeled residues indicate the limits of individual domains 
and the disordered loop in domain I. Residues Arg661 to Thr669 of the shown 
protomer are in gray because they belong to domain III of a neighboring 
protomer. Residues Arg661 to Thr669 of the other neighboring protomer are 
included here and shown in yellow, because they contribute to a sheet in 
domain III of the shown protomer. Disordered segments are shown as dots of 
appropriate color. Disulfides are shown in ball-and-stick representation. 
Cysteines are numbered according to (A) C) gB trimer. Protomer A is the 
same as in (B). Protomer B is shown in white and protomer C ingray. D) 
Accessible surface area representation of gB trimer. The coloring scheme is 
the same as in the rest of Fig. 9.1 generated images with the use of pymol, 
but figure is adapted from Heldwein et al 2006. 
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in this region abrogate function (176). Similar hydrophobic membrane proximal regions 
of other fusion proteins have been suggested to have a role in fusion (79,124). 
All 10 cysteine residues in the ectodomain of HSV-2 gB are involved in disulfide 
bridges and this conformation is expected to be conserved in all the herpesvirus gBs 
(130), although it may differ slightly in cytomegalovirus gB (105). gB has six N-linked 
glycosylation sites and several sites for O-linked glycosylation (82). 
When the sequence of gB is compared with that of other fusion proteins, little 
similarity is noticed. Some authors have reported that the spacing of conserved, essential 
glycines in the C-terminal hydrophobic domain is typical of fusion proteins (176). The 
gB proteins of VZV, Bovine herpesvirus (BHV), HHV8, and PrV are cleaved during 
maturation near residue 490. Residues in this region constitute a typical furin cleavage 
signal. This cleavage site was deleted from BHV gB without any noticeable change in 
the phenotype of the viruses (88). Moreover, HSV gB lacks this signal and is not cleaved 
suggesting that proteolytic cleavage is not necessary for gB function. 
2. Crystal Structure 
In 2007, Heldwein et al (76), crystallized and solved the structure of nearly the 
whole ectodomain (a.a. 103 to 730) of HSV gB (Fig. 9). This secreted protein was 
constructed by inserting a stop codon at the beginning of the first hydrophobic domain, 
expressing it in a baculovirus expression system, and purifying it via immunoaffinity 
column chromatography. To obtain a suitable crystal form, Dr. Heldwein treated gB730t 
with trypsin, which removed the first 109 amino acids. 
Various features of the crystal structure suggest that gB is a fusion protein. The 
structure includes three protomers; analytical ultracentrifugation shows that the protein is 
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a trimer in solution at neutral and low pH values (Fig 9). The protein is a 160 A tall by 
80 A by 80 A elongated spike, which agrees with previous EM data in size and shape 
(168). The bulk of each trimer coils around the others with a left-handed twist. 
According to Heldwein et al "there is no trimerization domain, per se, but multiple 
contacts between the protomers contribute to overall trimer stability ." 
Each protomer has been divided into five domains: domain I is the base, domain 
II is the middle, domain III is the a-helical core, domain IV is the crown, and domain V is 
the arm. Domain I is composed of a continuous polypeptide chain (residues 153 to 363), 
and has the fold characteristic of a pleckstrin-homology (PH) domain (96). In 
cytoplasmic proteins with such domains, this fold serves as a scaffold for phosphoinosital 
binding and protein-protein interactions (95). Two loops of domain I extend toward the 
viral membrane. These loops are similar in structural features to the fusion loop of the 
class II proteins. Do these loops behave as the fusion loop of class II proteins and the 
two loops of VSV G? Are these loops functionally homologous in gB? This is the 
underlying question that guided the majority of my thesis. 
Domain II is comprised of two discontinuous chains (residues 142 to 153 and 364 
to 469) and it contains another PH domain. Residues 460 to 491 are disordered in 
domain II of this crystal structure and this is most likely due to tryptic cleavage at 
arginine 474, which would potentially destabilize this loop. Interestingly, this is the site 
of post-translational cleavage in gBs of BHV and HCMV. 
Domain III is comprised of three discontinuous chains (residues 117-133, 500-
572, and 661-669). It is mostly an extended a-helix of about 50 residues, which leads 
into a small a-helix and a P-sheet. This central a-helix along with its counterparts from 
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the other two protomers form the central coiled coil, a structure clearly reminiscent of the 
central helix of class I fusion proteins. In those proteins, this feature serves as an 
"anchor" for structural rearrangements that occur during fusion. The central a-helix is 
important for trimer stability and remains relatively static while changes occur around it, 
and it is of paramount importance in fusion. In gB, the majority of the trimer contacts are 
in this region, but nothing is known about movements in the molecule. 
Domain IV is comprised of two discontinuous segments (residues 111-116 and 
573-660). It is the globular crown, another structural feature reminiscent of class I fusion 
proteins. In those proteins, receptor binding sites are often located in this region. In 
HSV gB, this domain is comprised of P-sheets with large loops in between. I have 
examined these loops by structure-based mutagenesis for evidence of a role in cellular 
receptor binding. This is the focus of the appendix (Chapter V) of this dissertation. 
Domain V (residues 670-725) stretches from the top of the molecule to the 
bottom in the form of an extended chain. The C-terminal region of this chain is a second 
extended, although much shorter a-helix. Residues in this domain have no contacts with 
the rest of the polypeptide chain, but fit in the groove between the core domains of the 
other two protomers. This tertiary interaction likely plays some role in trimer 
stabilization. The remainder of the gB full length molecule, including the two other 
hydrophobic regions is not included in the crystal structure, but would extend from the 
most C-terminal portion of this domain. 
Because gB is highly conserved in sequence among the other herpesviruses, it is 
likely that this structure will be similar in all of them. The structure of gB is far more 
similar to the post-fusion form of G than to the pre-fusion form. Also, the 
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transmembrane domain and the fusion loops are at the same end of the molecule, in the 
classical hairpin configuration typical of the post-fusion forms of class I and II fusion 
proteins. However, the TMR ad the fusion loops are also at the same end in the pre-
cision form of G. Whether the solved structure of gB is that of a post-fusion form will be 
best resolve by solution of the other structure. 
3. gB Function 
gB has long been suspected of being the viral fusion protein of herpesviruses. 
Particular viral isolates were observed to cause massive cell-cell fusion, called syncytia 
(multinucleated bodies). Some did so without protein synthesis (fusion from without), 
and others did so as a result of viral protein synthesis (fusion from within). Many of the 
syncytial mutants were mapped to point mutations in gB although some mapped to other 
glycoproteins such as gK (139). Along the same lines, viruses with different rates-of-
entries (151) into cells or with increased neuroinvasiveness (192) were also sequenced. 
These phenotypes were mapped to the gB ectodomain. 
Several other observations suggested that gB behaves as a typical fusion protein. 
For example, the Ebola and Marburg viruses (Filoviruses), Vaccinia virus 
(Orthopoxvirus), the murine Hepatitis virus (MHV, Coronavirus), the lymphocytic 
choriomeningitis virus (LCMV, Arenavirus) and herpes simplex virus enter into host 
cells via cholesterol rich microdomains. SFV El binds cholesterol as a necessary event 
for insertion of the fusion loop into the membrane (85,175). During viral fusion, gB is 
the only component of the HSV fusion complex that associates with lipid rafts (9). Along 
with gC, HSV-1 gB binds heparan sulfate and, to a lesser degree, chondroitin sulfate 
during entry (167). A polylysine domain (a.a. 68-76) is responsible for gB binding to 
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heparan; but viruses with a gB lacking this domain are still infectious. But as expected, 
the binding capacity of the virion is reduced (93). 
The HPSG analog heparin was used to compete with gB and gC for cell binding. 
Heparin completely blocks binding of gC to cells and also could displace gC after it 
attached (172). In contrast, heparin blocked only 80% of gB binding and could not 
remove it from cells. These data suggested that gC attaches only to heparan on the cell's 
surface but gB binds another cell surface moiety in addition to heparan and chondroitin 
sulfate. Soluble gB was shown to block entry of virus into cells lacking either heparan 
and/or chondroitin sulfate (Gro2C and Sog9 cells, both derived from L cells) in a dose-
dependent and saturable manner (8). These data suggest that gB binds a non-heparan 
receptor that is necessary for entry into L cells, and perhaps others as well. Recently 
PUJRa has been identified as a gB receptor on certain cell types (153). 
4. gB Functional Regions 
Much work has been done on HSV gB and the various homologues in 
herpesviridae. It is clear that the 129 a.a. cytoplasmic domain is important in fusion 
because syncytial phenotypes map to this region (104, 151). Some information on 
functional regions within the 773 a.a. ectodomain was obtained by linker insertion 
mutagenesis (20,21, 101,103). Four groups have had varying levels of success in 
identifying functional regions by linker-insertion mutagenesis. 
Very early, Cai et al. (20) showed that a two amino acid insertion at residue 189 
abolished fusion activity. This insertion is in domain I (Fig. 9B) highlighting it as a 
functional region (136). More recently, Li et al. chose linker-insertion targets by using an 
algorithm to predict loops in the structure of HSV-2 gB (101). They hypothesized, that if 
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properly targeted, loops would be more tolerant of insertions. Of 18 total mutants, they 
identified two loci in domain II (at a.a. 354 and 403, a.a. numbers adjusted to correspond 
with by homologous residues in HSV-1) that yielded non-functional, but properly folded 
proteins. In addition, an insertion at a.a. 658 (HSV-1 numbering) produced properly 
folded, non-functional gB proteins deficient in oligomerization. These data highlight 
domain II as a functional region and support previous work by Laquerre et al., that 
identified residues 626-676 as the oligomerization domain (94). The remaining 11 
mutations constructed by Li et al. yielded misfolded proteins. Interestingly, all of the 
mutations in the first 300 amino acids of gB-2 yielded misfolded proteins. This region is 
likely flexible as it was sensitive to trypsin cleavage. Although it is not included in the 
structure, these data suggest it is important for gB folding. Moreover, several epitopes 
for virus neutralizing mAbs map to this region and the HSPG binding region (a. a. 68-76) 
is located here as well (93). 
Lin et al. (103) completed a similar study of HSV-1 gB using a random linker-
insertion approach. Of 81 mutants, only 27 were expressed on the cell surface (33%). 
The majority of these were correctly folded, as determined by cELISA with mAbs against 
conformational epitopes and two (insertions at a.a. 495 and 497) permitted only partial 
fusion. Interestingly, these insertions are both located in the linker region between 
domain II and domain III. Eleven mutations spread across the length of gB, yielded 
properly folded non-functional proteins, thus identifying four important regions of gB 
involved in function (Fig. 10A & B). Four insertions were in domain I (at a.a. 185, 187, 
261, 265) near the fusion loops. One insertion was in domain II at a.a. 408. Six 
insertions identified a small region on the border of domains III/IV (a.a. 663, 665, 667, 
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Figure 10. Mapping of functional regions on the structure of gB as defined by 
A) & B) random linker-insertion and C) epitope mapping of mAbs with virus 
neutralizing activity. A) Sphere model with each protomer colored a different 
shade of gray. The amino acids bounding each insertion site are colored according 
to the domain or region to which each maps. Insertion sites in all three protomers 
are colored so that all surface insertion sites can be seen in one view. B) Ribbon 
model with the domains and regions of one protomer colored according to fig. 9. 
The insertion sites into the cavity of the trimer are indicated by dark blue coloring of 
the residues displayed in space-filling mode. C) Epitopes are rendered on an 
accessible surface area representation of the gB trimer. FR1 to FR3 are indicated 
with circles. Since FR4 is present in an unresolved region of gB, it is symbolically 
represented with a question mark. Colors are as defined in fig. 9. FR1, FR2, and 
FR3 identified by Dr. Bender C) overlap with the first three functional regions 
identified by Lin et al. A) and B). 
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671, 673), that is within the previously identified oligomerization domain (94). Four 
more insertions were near the C-terminus of the ectodomain (a.a. 725, 730, 732,742). 
Florent Bender in our lab took a very different approach (7) to identify functional 
regions. Hypothesizing that anti-gB mAbs with neutralizing activity against virus bind 
functional regions in gB, he mapped the epitopes of several of these antibodies (Fig IOC). 
By this method he identified five functional regions spread across the length of gB and 
comprised of several structural domains. Functional region 1 (FR1) was identified by 
mAbs that bind domains I and V, near the putative fusion loops. This group is 
represented by SS55. FR two is in domain II and represented by C226. FR three is in 
domain IV and is represented by SS10. FR four resides in portion of domain II that was 
not included in the crystal structure. In addition, another functional region was identified 
in the N-terminus of gB, also not included in the structure. Despite their very different 
approaches, FRs one, two, and three identified by Dr. Bender overlap with the first three 
functional regions identified by Lin et al (103). 
Thus, it seems apparent that each domain of gB plays a functional role in fusion 
and support the concept that gB is a complex protein that functions through concerted 
efforts spread across the full length of the protein. Interestingly, mAbs representative of 
FR one and FR three (SS55 and SS10), located at opposite ends of gB, neutralize virus 
entry and block attachment of soluble gB to cells (7, 8). This would suggest that both 
domain I and domain IV participate in the cell binding activity of soluble gB. The 
potential significance of this will be discussed below. 
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E. AIM OF PRESENT STUDIES 
Two loops in gB, a.a. 173-179 and 258-265, are structurally homologous to the 
fusion loops of VSV G (76,145). I hypothesized that they function as fusion loops and 
carried out structure-based mutagenesis to test this hypothesis. In chapter III, I report that 
three of the five tested residues, W174, Y179, and A261, are essential for gB's function 
in cell-cell fusion. I propose that gB has internal fusion loops, functionally homologous 
to those of VSV G and class II fusion proteins, that are an important functional domain 
and possibly interact with the target cellular membrane. 
In chapter IV, I completed the mutagenesis of both gB fusion loops, including 
charged amino acids in these regions. Using established cell-cell fusion and virus-cell 
fusion assays, I characterized the importance of each residue in gB dependent fusion to 
establish the functional architecture of the gB fusion loops. Unexpectedly I identified 
several additional amino acids, including two that are charged, which play key roles in 
fusion. Based on these results and those from chapter three, four soluble gB proteins, 
each with single point mutations in the fusion loops were generated. I characterized these 
proteins, and similar homologues in the full-length gB background, in several functional 
assays to define possible mechanisms by which mutations to the gB fusion loops may 
inhibit gB dependent fusion. 
II. MATERIALS AND METHODS 
1. Cells and viruses. Mouse fibroblast L-cells were grown in DMEM with 10% FBS. 
Mouse melanoma cells B78H1 cells, engineered to express the gD receptor nectin-1 
(CIO), were grown in DMEM supplemented with 5% FBS and 500 ng/ml of G418 (117). 
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For the fusion assay, CHO-K1 and CHO-A12 (CHO-K1 cells engineered to express 
HVEM) cells were grown in F12 medium containing 10% FBS. CHO-K1, CHO-A12, 
and CIO cells were kindly provided by P. G. Spear. L-cell, Gro2C, and Sog9 cells were 
generous gifts from F. Tufaro (6). K082 virus was kindly provided by S. Person (21)and 
VB38 cells were gifts from D.C. Johnson (52). 
2. Construction ofgB mutant molecules. The QuikChange site-directed mutagenesis kit 
(Stratagene Cloning Systems, La Jolla, CA) was used to generate mutant gB constructs as 
recommended by the manufacturer and as described previously (36). Briefly, primers 
designed to mutate individual gB residues were used to amplify the entire pPEP98 
plasmid (gB in the pCAGGS background) by PCR (137). The reaction products were then 
treated with Dpnl to digest methylated template DNA and used to transform competent 
bacteria (Invitrogen One Shot Topi OF). The mutations were confirmed by sequencing of 
the entire gB gene. pBH730 encodes gBW174Y, pBH739 encodes gB W174R , pBH776 
encodes gB W174K, pBH839 encodes F175K, pBH807 encodes G176K, pBH812 
encodes H177A, pBH784 encodes R178A, pBH777 encodes Y179S, pBH877 encodes 
Y179K, pBH792 encodes R258A, pBH876 encodes E260A, pBH750 encodes gB 
A261W, pBH732 encodes gB A261D, pBH778 encodes gB W174R/A261D, pBH733 
encodes gB F262L, pBH736 encodes gB F262D, pBH809 encodes H263A, pBHR786 
encodes R264A encodes, and pBH??? encodes Y265R. 
3. Antibodies and reagents. Rabbit serum R69 was raised against full-length gB-1 
purified from infected cells (80). Monoclonal antibody (mAb) DL16 was generated using 
extracts of cells infected by HSV-1 and -2 as immunogens. It recognizes a trimer-
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specific conformational epitope on gB (7). Hybridoma cell lines expressing monoclonal 
antibodies (mAbs) to gB, numbered SS10 to SS145, were generated. SS10, SS55, and 
SS145 both react with different conformational epitopes on gB (7). SS10 and SS55 have 
potent virus neutralizing activity. SS63 recognizes a linear epitope at the C-terminus of 
the ectodomain (a.a. 695-725). Hybridoma cells were injected into mice to raise ascites. 
Immunoglobulin G (IgG) was purified from sera and ascites fluid with HiTrap protein G 
1-ml columns (Amersham Pharmacia Biotech) and dialyzed against phosphate-buffered 
saline (PBS) (7). Anti-mouse and anti-rabbit secondary antibodies coupled to horseradish 
peroxidase (HRP) were purchased from Kirkegaard and Perry Laboratories. The anti c-
myc mAb 9E10 (49) was used as a negative control for immunoprecipitation. 
4. Immunoprecipitation and western blotting. Anti-gB mAbs were used to 
immunoprecipitate gB from total cell lysates of transfected L-cells. Cell extracts were 
diluted in lysis buffer and incubated with either DL16, SS55, SS145, or anti c-myc 
(negative control) IgG for 18 h at 4°C. Proteins were precipitated with protein A-agarose 
beads (Gibco BRL) for 2 h at 4°C, subjected to electrophoresis on a 10% SDS-
polyacrylamide gel, and detected by Western blotting with the anti-gB pAb R69 IgG. 
Membranes were incubated with secondary antibody (goat anti-mouse) coupled to 
horseradish peroxidase. Membranes were washed with 0.2% Tween 20 (BioRad) in PBS 
and visualized by exposure to film after addition of a chemiluminescent substrate (ECL; 
Amersham). 
5. CELISA. To detect gB cell surface expression, we used a modification of a cell-based 
enzyme-linked immunoabsorbent assay (CELISA) method (62,118). CHO-K1 cells 
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growing in 96-well plates were transfected with the T7 polymerase and gD, gH, gL, and 
gB plasmids by using 40 ng of each plasmid/well and 0.5 \xl of Lipofectamine 2000 
(Invitrogen), both diluted in Opti-MEMl (Gibco). Cells were exposed to the DNA-
Lipofectamine 2000 mix for 5 h before it was replaced with growth medium. Cells were 
grown overnight at 37°C, fixed in 3% paraformaldehyde, and rinsed three times with PBS 
(Ca+/Mg+). Cells were incubated for 1 h at room temperature (RT) with polyclonal 
antibody (PAb) R69 IgG diluted in 3% bovine serum albumin in PBS, rinsed with PBS 
three times, and incubated for 30 min at RT with goat antirabbit antibodies coupled to 
horseradish peroxidase. Following another three washes with PBS, cells were rinsed with 
20 mM citrate buffer (pH 4.5). 2,2'-Azino-di(3-ethylbenzthiazoline) sulfonic acid 
peroxidase substrate (Moss, Inc.) was added, and the absorbance at 405 nm was recorded 
using a microtiter plate reader. Background was subtracted and data were normalized to 
WTgB. 
6. Quantitative fusion assay. To detect cell-cell fusion, I modified the luciferase 
reporter gene activation assay previously described (133,137). Effector cells (4xl04 
CHO-K1 cells per well), growing in 96-well plates were transfected with plasmids 
encoding T7 RNA polymerase, gD, gH, gL, and one of the mutant gB plasmids described 
above. 40 ng of each plasmid and 0.5ul of Lipofectamine 2000/well (Invitrogen), both 
diluted in Opti-MEMl (Gibco), were added to cells in each well. Transfections were 
performed in triplicate. To prepare receptor-bearing target cells, CHO-HVEM12 cells 
growing in 6-well plates were transfected with 10 (0,1 of Lipofectamine 2000/well and 4 
ug/well of a plasmid encoding the firefly luciferase gene under control of the T7 
promoter. After 5 h at 37 °C, the transfection mixes were replaced with fresh medium and 
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incubated for another hour at 37°C. Target cells were trypsinized, and 4 xlO4 cells/well 
were added to the effector cells and co-cultivated at 37°C for 18 h. Cells were washed 
once with PBS, lysed with 30 ul/well of lx reporter lysis buffer (luciferase assay system; 
Promega), and then frozen. To measure the extent of fusion, 25 ul of each sample were 
mixed with 100 u.1 of luciferase substrate (Promega) and immediately assayed for light 
output with a Luminoskan Ascent (Thermo Labsystems). Plasmids encoding the firefly 
luciferase gene (pT7EMCLuc), T7 RNA polymerase (pCAGT7), gB (pPEP98),gD 
(pPEP99), gH (pPEPlOO), and gL (pPEPlOl) were gifts of P. Spear (133,137). 
7. Syncytium formation assay. B78H1-C10 cells growing in 24-well plates were co-
transfected with plasmids encoding gD (pPEP99), gH (pPEPlOO), gL (pPEPlOl), and one 
of the gB mutants. 500 ng of each plasmid and 5 (j.1 of GENEPorter reagent in 600 ul 
DMEM/well were added each well of cells and incubated for 3h at 37°C, after which it 
was replaced with growth medium. After an 18 h incubation at 37°C, cells were fixed 
with methanol, stained with Giemsa (Gibco BRL) for 10 min, and examined for 
syncytium formation by microscopy (22, 36). 
8. Immunofluorescence. I used a modification of a previously described technique (22). 
B78H1-C10 cells were seeded onto glass coverslips in 24-well plates at 7.5 x 104 
cells/well and cultured overnight. Cells were transfected with mutant gB expression 
plasmids using LipofectAMINE 2000 (Invitrogen). 18 h post-transfection, cells were 
fixed with 3% paraformaldehyde for 20 min, quenched with 50 mM NH4C1 for 20 min 
and then incubated for 30 min with 0.5% BSA in PBS (blocking solution). Cells were 
incubated with pAb R69 IgG (diluted 1:1000 in blocking solution) at RT for 30 min, 
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washed with PBS, and then incubated with a-rabbit secondary coupled to Alexa 488 
(Molecular Probes) (1:1000 in blocking solution) for 30 min. Coverslips were washed 
three times with PBS, once with water and mounted on slides in ProLong Antifade 
mounting solution (Molecular Probes). DAPI (4', 6'-diamidino-2-phenylindole) was 
added to the mounting solution to stain cell nuclei. Cells were observed under a Nikon 
Eclipse E600 microscope at 400x magnification using a 488 nm filter. 
9. Complementation. This assay was done as previously described for complementation 
of gD-negative virus by WT and mutant for of gD (109) except that Vero cells in six-well 
plates were transfected with 1.0 ug of plasmid expressing WT or mutant forms of gB and 
3.5 ul of Lipofectamine 2000 and later infected with the gB-negative mutant, HSV-
1(KOS)K082 (21). Virus stocks were prepared and titrations performed on VB38 cells 
(52). Virus and VB38 cells were gifts of D. C. Johnson. 
10. Production and purification of soluble HSV-1 glycoproteins. gB(730t) comprises 
the first 700 amino acids of the mature gB ectodomain expressed from a baculovirus 
expression system. The amino acids are numbered starting at the first methionine of gB. 
The truncated protein was purified from baculovirus-infected insect cells (sf9) using a 
DL16 immunoabsorbent column. Bound gB was eluted with 3 M KSCN, then dialyzed 
and concentrated essentially the same way as described for in (9). 
Secreted truncated versions of gB-1 with the following mutations Y179S, H263A, 
W174R, and R264A were generated by changing the codon at a. a. 730 of pBH777, 
pBH809, pBH739, and pBH786, respectively, into a stop a codon that also created a Bell 
restriction site. Thus, this ORF stopped at amino acid 730 as with WT gB730t. Plasmids 
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coding for the secreted gB mutants were subcloned into pFB688, a baculovirus 
expression vector that expresses gB730t, by a Notl/Nhel double digestion within the gB 
coding sequence, and subsequent ligation. Recombinant baculovirus was generated as 
described in (157). The truncated protein was purified from baculovirus-infected insect 
cells (sf9) using a DL16 immunabsorbent column. Bound gB was eluted with 3 M 
KSCN, then dialyzed and concentrated essentially the same way as described for 
gD(306t) (157). Mutant gB730t proteins were named gB730t-Y19S, gB730t-H263A, 
gB730t-W174R, and gB730t-R264A and are encoded by pBH861, pBH868, pBH890, 
and pBH873, respectively. 
11. Soluble gB Liposome Floatation Assay. Liposomes were purchased from Encapsula 
Nanosciences (Nashville, TN). The 0.4 nm liposomes have a molar ratio of 1.7:1 (egg 
phosphatidylcholine(PC):cholesterol) and are suspended in PBS (pH 7.4) at a 
concentration of 1.25 mg/ml. Some liposomes were fluorescently labeled by adding 
NBD conjugated phosphatidylcholine, purchased from Avanti Polar Lipids, INC 
(Alabaster, AL), to liposomes at 5 mol% of total PC. 
For experiments, 1 u,g of purified soluble protein was added to 25 ul of 
liposomes. The volume was adjusted by the addition of 24 ul 200 mM sodium citrate 
buffer. The 50 ul mixture was incubated at 37° C for lhr, adjusted to 1M potassium 
chloride by the addition of 450ul of 1.3 M sodium chloride, and incubated at 37° C for an 
additional 15min. The mixtures were adjusted to a volume of 500 ul 40% sucrose by 
addition of 300 ul of 66% sucrose. Samples were transferred to a TL55 tube (Beckman) 
and were overlaid with 4 ml of 25% (wt:vol) sucrose and 500 ul of 5% (wt/vol) sucrose 
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(all in ice cold PBS). Gradients were centrifuged for 3 h at 45,000 rpm at 4°C in a 
TLS55 rotor and seven 700 ul fractions were collected from top to bottom. Then 70 ul 
1% NP-40 was added to each sample to lyse liposomes at a final concentration of 0.1% 
NP-40. 
I used a capture enzyme-linked immunoabsorbent assay (ELISA) to quantitate the 
amount of gB in each fraction. ELISA plates were coated with 50 ul of a 10 ug/ml 
concentration of SS145 IgG diluted in PBS/well. After an overnight incubation at 4°C, 
plates were exposed to blocking solution (PBS pH 7.4 containing 5% milk and 0.2 % 
Tween 20) for 1 h. Each fraction was diluted in PBS and incubated on the plate for 1 h at 
RT. Captured gB was detected by adding 50 ul of a 1 ug/ml concentration of PAb R69 
IgG/well followed by goat anti-rabbit antibody coupled to horseradish peroxidase. Plates 
were rinsed with 20 mM citrate buffer (pH 4.5), ABTS peroxidase substrate was added, 
and the absorbance at 405 nm was recorded by using a microliter plate reader. 
For western blot, fractions were subjected to electrophoresis on a 10% SDS-
polyacrylamide gel, and detected by Western blotting with R69 IgG. gB was detected as 
described above. 
12. Inhibition of viral entry by soluble gB730t and mutants. Soluble gB 730t was used 
to block entry of HSV into cells as described in (8) Cells were seeded in 96-well plates 
and grown overnight to reach 3.25x 104 cells per well. They were then incubated for 1 h 
at 4°C with serial dilutions of soluble glycoproteins diluted in DMEM containing 5% 
FCS and 30 mM HEPES (DFH). Glycoproteins were allowed to bind to cells at 4°C for 
30 min then HSV-1 KOS/tkl2 (expressed (3-gal from the IE promoter) was added at an 
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MOI of 10, and incubated at 4°C for 30 min to allow virus attachment. The temperature 
was then shifted to 37°C to allow synchronous infection. Cells were lysed 6 h later by the 
addition of an equal volume of PBS containing 1% NP-40. J3-Galactosidase activity was 
determined by the addition of substrate (chlorophenol red-f5-D-galactopyranoside; Roche) 
and measurement of absorbance at 570 nm in a microtiter plate reader. Background, 
obtained from uninfected wells, is subtracted and values are expressed as % uninhibited 
entry (no protein added). 
13. Binding of soluble glycoproteins to the cell surface by CELISA. I used a 
modification of the cellular enzyme-linked immunosorbent assay (CELISA) mentioned 
above. As before cells were seeded in 96-well plates and grown overnight to reach 3.25 
xl04 cells per well. They were then incubated for 1 h at 4°C with serial dilutions of 
soluble glycoproteins diluted in PBS. After three washes with ice-cold PBS, cells were 
fixed with 3% paraformaldehyde. Cells were then rinsed three times with PBS and 
incubated 1 h with lOug/ml of R69 IgGs that had been diluted in PBS containing 3% 
BSA. After three washes with cold PBS, cells were further incubated for 1 h with HRP-
conjugated anti-rabbit antibodies. Following another three PBS washes, cells were rinsed 
with 20 mM citrate buffer, pH 4.5. 2,2 di-Azinobis(3-ethylbenzthiazolinesulfonic acid) 
(ABTS) peroxidase substrate (Moss, Inc.) was added, the absorbance at 405 nm was 
measured with a micro titer plate reader. 
14. Construction of Venus EYFP tagged glycoproteins to study interactions of proteins 
using bimolecular complementation. The construction of Venus EYFP tagged gB (Be) 
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and gH (Hn) wild-type glycoproteins was described previously (2). Briefly, the genes for 
each glycoprotein were PCR amplified such that the natural stop codons was excluded to 
allow in frame ligation with N- or C-terminal portions of the EYFP Venus ORF. The 
VenusN (1-173) or VenusC (174-239) halves were PCR amplified using pCS2 as a 
template (125). A translation stop codon was incorporated after codon 173. To construct 
VenusC tagged gB fusion loop mutants, plasmids encoding the full-length gB mutant 
proteins pBH732 (A261D), pBH739 (W174R) and pBH777 (Y179K) were digested with 
EcoRLTmll restriction enzymes. Digestion yielded 1715bp fragments that were ligated 
into pCW803 digested with EcoRI/Pmll restriction enzymes. 
15. Fluorescence assay for bimolecular complementation. B78H1-C10 cells were 
seeded on glass coverslips and cultured overnight at 37°C. They were then transfected 
over night with 60ng of each plasmid. Cells were fixed with 3% paraformaldehyde for 20 
min at room temperature (RT), and then the remaining paraformaldehyde was quenched 
by incubation of the coverslips in 50 mM NH4CI for 10 min at RT. Fixed cells were 
incubated in phosphate-buffered saline (PBS) with 10% goat serum for 30 min at RT and 
then labeled with anti-gB mAbs A22+SS55 (7) or anti-gH pAb R137 (135). After being 
washed with PBS, cells were incubated for 30 min with AlexaFluor594-conjugated goat 
anti-IgG (Invitrogen) secondary antibody diluted in 10% goat serum-PBS. The coverslips 
were rinsed three times with PBS, once with water, mounted on slides with ProLong 
Gold antifade reagent (Invitrogen) for fluorescent microscopy. For confocal microscopy, 
we used a Nikon TE2000-U inverted microscope coupled to a PerkinElmer confocal 
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imaging system. A two-line argon krypton laser emitting at 488 and 568 nm was used to 
excite the fluorescence of Alexa Fluor 594. 
To trigger fusion by soluble gD (180), cells were transfected with plasmids for 
tagged forms of gB and gH using GenePorter (Gene Therapy Systems) along with 
untagged gL and incubated for 20h at 37C. Cells were fed with fresh medium 
supplemented with 250ug/ml gD306t for up to 4 h. Cells were fixed and stained as above 
and examined by confocal microscopy. 
III. MUTATIONAL EVIDENCE OF INTERNAL FUSION LOOPS IN HSV 
GLYCOPROTEIN B 
SUMMARY 
To examine whether the gB putative fusion loops are important for gB function, I 
mutated potential membrane interacting (hydrophobic) residues to charged amino acids. 
Of most interest were mutant gB proteins that were expressed on the cell surface, 
recognized by monoclonal antibodies against conformational epitopes, but lacked the 
ability to function in cell-cell fusion assays. Of the five hydrophobic amino acids 
targeted in these loops, I show that tryptophan 174, tyrosine 179, and alanine 261 are 
integral in the function of gB. My data suggest that these loops comprise an important 
functional domain. I hypothesize that two loops in domain 1 of HSV gB are fusion loops 
that function together to penetrate the target cellular membrane. My data are further 
evidence that gB is a viral fusogen, and suggest clues as to how gB may function. 
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RESULTS 
Selection of Target Residues 
The similarity of the VSV G fusion loops to those of class II fusion proteins, and 
the high degree of structural homology between G and gB, guided selection of our targets 
for site-directed mutagenesis. Figure 11B illustrates the structural homology between the 
two proteins, the domains of each protomer are labeled according to the original 
publication (76,145). Domain IV of VSV G, including the two loops, is conserved in gB 
as domain I (145). The primary sequence of gB domain I loop 1 is 173VWFGHRY179 
and the primary sequence of loop 2 is 258RVEAFHRY265. Thirteen of these residues are 
labeled in figure 11C and each is colored according to loop. Nine are hydrophobic or 
non-polar (blue), while the remainder are charged (red) (Fig. 1 ID). Five of the 
hydrophobic residues (V259, F262, A261, W174, and Y179) are clustered and lie on the 
outer face of a ridge formed by the two loops of each protomer. V259 is conserved 
amongst all herpesviruses sequences analyzed except VZV. W174 and Y179 are 
conserved amongst the gB's of all alphaherpesviruses analyzed, whereas A261 and F262 
are conserved among all HSV -1 and -2 gB sequences analyzed (76). Introduction of a 
charged residue in place of a hydrophobic amino acid in class I and class II fusion 
peptides is detrimental to fusion (1, 55, 63). It has been postulated that charged residues 
cannot insert into the target membrane. To determine the functional importance of the 
five residues in the hydrophobic cluster, I mutated each to a charged residue. F262 was 
the most obvious choice because its location and aromaticity resembles key residues in 
the fusion loops of the class II and VSV fusion proteins (120,142,145). 
49 
Figure 11. HSV gB and VSV G are structurally homologous, including the 
putative fusion loops. A) Ribbon diagram of HSV-1 gB. B) Comparison of 
HSV-1 gB and VSV G crystal structures {Heldwein, 2006 #10; Roche, 2006 #9}. 
One protomer of each trimer is shown, and they are labeled according to their 
respective domains. Four of the five domains of gB are structurally homologous to 
VSV G. C) Close-up of the gB putative fusion loops of one protomer {Heldwein, 
2006 #10}. The loops are colored to match A, with nitrogens in blue and oxygens 
in red. D) A molecular surface representation of the the putative fusion loops at 
the tip of domain I. This view was derived from the one in A by rotating the lower 
tip of the molecule by 90° towards the viewer. Hydrophobic residues are colored in 
purple, and the surrounding charged residues, in red. All structural figures were 
generated, in part, using PyMOL {Delano, 2002 #129}. Unless stated otherwise, 
all structures are colored by secondary structure succession. 
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Rationale for Construction of Additional Mutants 
I mutated F262 to D, W174 to both R and K, Y179 to K, V259 to R, and A261 to 
D. Based on evidence that previous mutagenesis of HSV gB yielded few properly 
processed proteins (21,101,150) I made more conservative substitutions. I mutated 
Y179, A261 and F262 to S, W and L, respectively. W174 was mutated to Y because 
although this residue is a tryptophan in alphaherpesviruses, it is a tyrosine in gB of CMV, 
HHV6, EBV, and HHV8 (76). In addition, I generated the double mutant 
W174R/A261D so that one amino acid in each loop was altered simultaneously (Table 1). 
Wild-type 
Residue 
W174 
Y179 
V259 
A261 
F262 
Charged 
Residue 
R 
K 
R 
D 
D 
Alternate 
Residue 
Y 
G 
W 
L 
Structural 
Feature 
Putative fusion 
loop 1 
Putative fusion 
loop 1 
Putative fusion 
loop 2 
Putative fusion 
loop 2 
Putative fusion 
loop 2 
Table 1 . Hydrophobic Ridge Fusion Loop Mutants 
Expression of Mutant Proteins in Mammalian Cells 
I tested each mutant protein for expression by transfecting L-cells with plasmids 
expressing each construct. Proteins in the total cell lysate were separated by SDS-PAGE 
under denaturing and reducing conditions. I probed the blots with an anti-gB pAb (R69) 
and with a mAb that detects an epitope (a.a. 697-725) near the C-terminus of the gB 
ectodomain (SS63) (7). 
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All mutant forms of gB migrated similarly to full-length wt gB, and were detected 
by R69 and SS63 (not shown). The level of W174K and A261W expression was reduced 
with respect to the other mutants and to WT gB. 
Mutant gB Proteins are Immunoprecipitated with mAbs Against Conformation 
Dependent Epitopes 
To ensure that the gB mutant proteins were properly folded, I immunoprecipitated 
each one with mAbs (DL16, SS55, and SS145) against conformational epitopes that map 
to different regions of gB (7). SS55 has strong virus neutralizing activity and recognizes 
an epitope that includes domain I and V (Fig. IOC). Thus, I rationalized that it would be 
sensitive to any structural changes caused by the mutations. SS145 recognizes an epitope 
in domain IV (Fig. IOC). Because all fusion proteins function as trimers, it was 
important to ensure that none of the mutations in gB affected trimerization. This was 
tested with mAB D16, whose epitope has not been mapped, but only recognizes the gB 
trimer. 
Mutant gB proteins were immunoprecipitated from transfected L-cell lysates (Fig. 
12). All mutants except W174K and V259R were immunoprecipitated by DL16, SS55, 
and SS145. These data indicate that, for eight of the nine mutants, all three epitopes 
were intact and none of the mutations prevented trimerization. Repetitions show that 
differences in the amount of immunoprecipitated A261W are the result of lower protein 
levels, not a property of the mutant gB. W174K and V259R were not 
immunoprecipitated by any of the mAbs, suggesting that they were not properly folded. 
These mutants were not studied further. 
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Figure 12. Immunoprecipitation of mutant gB proteins from transfected L 
cells. gB mutant proteins were immunoprecipitated from lysates of transfected L 
cells using mAbs against conformational epitopes DL16 (lanes A), SS55 (lanes B), 
and SS145 (lanes C). An mAb against c-myc was used as a negative control 
(lanes D) {Evan, 1985 #117}. gB mutations are indicated at the top of the Western 
blots. WT gB is expressed from pPEP98 and the empty vector pCAGGS was 
used as a negative control. pAb R69 was used for detection of gB. Molecular 
weight markers are labeled on the left in KDa 
Cell-cell Fusion and Surface Expression of Mutant gB Proteins in CIO cells 
As another way to assess folding as well as transport, I examined the cell surface 
expression of the mutant gB proteins by immunofluorescence (IFA) of intact and 
permeabilized cells. CIO (B78 cells stably expressing nectin-1) cells growing on 
duplicate coverslips were transfected with plasmids encoding each mutant. Cells on one 
coverslip were permeabilized (control for expression), and the others were not. Both sets 
of coverslips were stained with R69 (anti-gB pAb) and Alexa-488-coupled secondary 
antibody. 
CIO cells were transfected with the WT gB, empty vector (control), and one of 
eight mutants. WT gB and the two gB mutants were displayed on the cell surface as 
were the other six gB mutants (Fig. 13). Thus, gB mutants W174Y, W174R, A261W, 
A261D, Y179S, Y179K, F262L, F262D, and W174R/A261D are properly folded and 
expressed on the cell surface. These results are consistent with the notion that loops are 
W174K Y179K " J / ™ 
A B C D A B C D A B C D 
9 7 -
F262L W174 
A B C D A B C D 
ii6—DjMPdfc:- •' •MiMii' 
97— : 
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more tolerant of mutations than other structural motifs, as eight of ten mutations of amino 
acids in the putative fusion loops of gB yielded properly folded and processed proteins. 
non-permeablized permeablized 
Figure 13. Immunofluorescence on intact C10 cells. Immunofluorescence on 
intact C10 cells was used to evaluate surface expression of gB mutant proteins. 
Proteins were detected using R68, an a-gB pAb and permeablized cells were 
analyzed to control for transfection. All mutants that formed syncytium were 
expressed on the surface. 
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Figure 14. Syncytium formation assay. To determine the ability of mutant gB 
proteins to participate in cell-cell fusion, C10 cells were transfected with plasmids 
encoding WT gD, WT gH, WT gl_, and either WT gB or one of the gB mutants: 
The cells were incubated for 18 hrs, methanol fixed, and stained with Giemsa. 
Syncytia are indicated by black arrows. 
I carried out two types of cell-cell fusion assays to determine the ability of the gB 
mutants to function. The first is a qualitative assessment of syncytium formation. CIO 
cells are transfected with expression plasmids for gD, gB, gH and gL, their synthesis and 
cell surface expression results in cell-cell fusion events leading to large multinucleated 
cells, or syncytia (123). Syncytium formation requires functional forms of all four of the 
HSV glycoproteins, and therefore can be used to test the effects of mutations in any one 
of the proteins. CIO cells were transfected with expression plasmids for WT gD, gH, gL, 
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and the WT gB or mutants. After 18h at 37°C, cells were stained with Giemsa to 
visualize syncytia. 
As expected, cells transfected with WT gD, gH, gL, and gB formed several large 
syncytia (indicated with black arrows) and those transfected with empty vector formed 
none. Cells transfected with gD, gH, gL, and either W174Y, W174R, Y179K, Y179S, 
A261W, A261D, and W174R/A261D were unable to form syncytia (Fig. 14). I expected 
F262 to be important for function because its location in the putative fusion loops of gB 
best resembled the location of aromatic residues in the fusion loops of VSV G and the 
class II fusion proteins. The mutant F262L supported syncytium formation. F262D was 
not tested in this assay because it was misfolded (see below). Nonetheless, these data 
suggest that W174, Y179, and A261 are important in gB function. 
Cell-cell Fusion and Surface Expression ofgB Mutant Proteins in CHO Cells 
It was still possible that some of the mutant proteins might exhibit quantitative 
differences in function when compared to wild-type gB. Therefore, I tested them using a 
quantitative luciferase based fusion assay in CHO cells (137). Effector cells were 
prepared by transfecting CHO-K1 cells with plasmids encoding T7 RNA polymerase, 
gD, gH, gL, and either WT gB or one of the gB mutants in a 96-well plate. A second 96-
well plate of effector cells was prepared in parallel to examine surface expression of each 
form of gB in the same experiment. Target cells were prepared by transfecting cells that 
stably express the gD receptor HVEM (CHO-HVEM12) with a plasmid encoding the 
luciferase ORF under control of the T7 promoter. The target and effector cells were 
mixed, incubated, and assayed for luciferase activity as a measure of cell-cell fusion. As 
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Figure 15. Cell-cell fusion activity and surface expression of gB mutants in 
CHO cells. A) Luciferase fusion assay. CHO cells stably expressing HVEM 
(CHO-A12) were transfected with a plasmid encoding the luciferase gene under 
the control of the T7 promoter and co-cultivated with CHO-K1 cells transfected 
with plasmids encoding T7 polymerase along with plasmids encoding gD, gH, gl_, 
and either WT gB or the indicated gB mutant. The cells were lysed and assayed 
for luciferase activity as a measure of cell-cell fusion. The luciferase value for the 
empty vector was subtracted (background), and all data are represented as % of 
WT activity. Each experiment was performed in triplicate. The data and standard 
deviations were derived from a minimum of three experiments. B) Cell-based 
ELISA (CELISA) was used as a measure of cell-surface expression of gB mutant 
proteins in CHO cells. Transfected cells were seeded into 96-well plates and 
expression of the indicated gB mutant on the cell surface was detected using pAb 
R69. 
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a control, effector cells that substituted empty vector for WT gB were prepared. These 
cells were co-cultured with target cells and the luciferase activity was subtracted as 
background. 
The fusion activity of the mutants was expressed as percent of fusion facilitated 
by WT gB (Fig 15A). Mutants Y179S, Y179K, F262D and W174R/A261D had no 
detectable activity in this assay, in agreement with the syncytium formation assay (Fig. 
14). Mutants W174R, A261D and A261W functioned minimally, also in agreement with 
results in Figure 4. F262L functioned at least as well as WT gB, confirming this same 
surprising result seen for syncytium formation. (Fig. 14). The mutant F262D was unable 
to function in cell-cell fusion, but was only expressed on the surface of cells at 30% of 
WT levels. I have little idea how much gB on the surface is adequate for WT levels of 
fusion. Although it was immunoprecepitated by all the mAbs, I assume that F262D is 
partially misfolded. For this reason, I can make no conclusions on the role of F262 in gB 
fusion. 
In fact, the only discrepancy noted was the case of W174Y, that did not promote 
syncytium formation, yet exhibited 46% of WT activity in the luciferase assay. Since this 
mutant, like the others, was expressed on the cell surface, I considered the possibility that 
fusion might be gD-receptor dependent. However, I obtained the same results when I did 
the the syncytium formation assay using B78H1 cells expressing HVEM and the 
luciferase fusion assay using CHO cells expressing nectin-1 (Figs. 14 & 15). 
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CONCLUSIONS 
The results of the two assays suggest that mutations of residues W174, Y179, and 
A261 seriously impair or ablate gB function. My goal in this study was to determine 
whether or not residues in the domain I loops of HSV gB have a role in fusion. These 
putative fusion loops clearly resemble and are structurally homologous to the known 
fusion loops of VSV G (Fig. 1 IB). I performed site-directed mutagenesis on five target 
residues to generate ten mutants from both loops of HSV-1 gB. Two did not fold 
correctly and another was not properly transported. The remaining eight mutants folded 
correctly and were expressed on the cell surface. Of those, all but two failed to function 
in cell-cell fusion suggesting the participation of the WT amino acid in a functional 
domain. Two of those residues, W174 and Y179, are in one loop and the third, A261, in 
the second loop. When one examines the structure in a surface representation of the 
bottom of gB, W174, Y179, and A261 are adjacent to each other in a hydrophobic ridge 
formed by the two domain I loops (Fig. 1 ID). 
IV. FUNCTIONAL ARCHITECTURE OF GLYCOPROTEIN B FUSION 
LOOPS AND MECHANISMS OF MUTATIONS INHIBITING HSV FUSION 
SUMMARY 
The goal of this study was to further define the functional architecture of the gB 
fusion loops. Together with chapter III, I have now mutated every residue in the gB 
fusion loops and evaluated their importance in gB function. Many of the hydrophobic 
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residues and two charged residues are critical for function of gB in cell-cell fusion and 
cell entry. Allison et al. and Kielien et al. used a variety of functional assays to determine 
the mechanisms of mutations inhibiting TBE E and SFV El protein dependent fusion, 
respectively (1, 84). Mutations in the fusion loop of E and El that impaired fusion also 
impaired liposome association and trimerization. This data provided evidence that the 
fusion loops were likely involved in direct membrane interactions and assisted in 
temporally linking membrane interaction and trimerization. Using these studies as a 
guide, I tested four gB mutants in several functional assays with the goal of determining 
their mechanisms of fusion inhibition. Four different soluble recombinant gB proteins 
were produced, each carrying one of the critical mutations. These mutant proteins were 
tested for their ability to bind liposome model membranes, bind cells, and engage a 
putative gB receptor to block virus entry. All of the mutants were impaired in liposome 
binding, emphasizing the importance of the fusion loops for target membrane insertion. 
In contrast, the mutant forms of gB blocked entry as well as WT gB, which suggest that 
the receptor binding domain is distinct from the fusion loops. Interestingly, all of the 
mutants were impaired in their ability to bind to the surface of Gro2C cells. Cell binding 
seems to be dependent on fusion loop integrity. In the fourth functional assay, full-length 
gB mutants were tested for their ability to interact with gH/gL. To our surprise, none 
were capable of this interaction. 
RESULTS 
Selection of Target Residues 
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The crystal structure of a truncated form of HSV gB (gB730t) revealed that it is a 
large trimeric spike in what may be a post-fusion conformation (Fig. 16A, B, & C) (76). 
The three residues that I showed to be critical for fusion (W174, Y179 and A261), are at 
Figure 16. HSV gB Hydrophoic ridge is surrounded by charged residues on 
the surface of the molecule. A) Ribbon diagram of HSV protomer and B) 
trimer. C) Surface accessible representation of gB trimer. In each, one protomer 
is colored by secondary structure succession. D) Close-up of the gB putative 
fusion loops, colored to match A),B), and C). D) Close-up of C), gB is turned 180° 
in the Z-axis, to focus on putative fusion loop. Surface representation is 
transparent to show sticks below. Hydrophobic residues are colored in blue and 
charged residues in red. 
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the bottom of the structure in domain I (72). Interestingly, six of the fourteen residues 
that comprise the domain I loops are charged (Fig 16D). Structurally, the hydrophobic 
residues of the ridge are surrounded exclusively by these charged residues (Fig 16E). I 
hypothesized that both charged and hydrophobic residues play important roles in gB 
function. 
To test this hypothesis I completed mutagenesis of the fusion loops by mutating 
three additional hydrophobic residues: F175, G176, Y265 to charged amino acids and six 
charged residues: H177, R178, R258, E260, H263, and R264 to alanines (Table 2). 
Target Mutation Fusion Loop 
F175 K I 
G176 K I 
H177 A I 
R178 A I 
R258 A II 
E260 A II 
H263 A II 
R264 A II 
Y265 R II 
Table 2. Mutations to Complete Mutagenesis of gB Fusion Loops 
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Four Fusion Loop Mutants are Impaired in Cell-Cell Fusion, but are Expressed on the 
Surface ofCHO Cells 
All mutants (Table 2) were tested for function using a quantitative luciferase 
based cell-cell fusion assay. CHO-K1 cells (effector cells) were transfected with 
plasmids encoding 17 RNA polymerase, gD, gH, gL, and either WT gB or one of the gB 
mutants in a 96-well format. A second plate of effector cells was prepared in parallel to 
examine cell surface expression of each gB mutant. Target cells that stably express the 
gD receptor HVEM (CHO-HVEM12) were transfected with a plasmid encoding the 
luciferase open reading frame under control of the T7 promoter. Target and effector cells 
were co-cultivated for 18 h and assayed for luciferase activity as a measure of cell-cell 
fusion. As a control, effector cells were prepared that substituted empty vector for WT 
gB and were co-cultured with target cells. 
Mutants exhibiting fusion activity below 20% of WT gB were considered to be 
non-functional, and those that were between 20% and 51% were considered to be 
significantly impaired. Previously I showed that the mutants Y179S, Y179K, W174R, 
A261D, A261W and W174R/A261D were non functional and that W174Y was 
significantly impaired (shown in Fig. 17A). Among the new mutants, G176K was non-
functional and three others were significantly impaired; F175K, R264A, and H263A 
functioned at 26%, 31%, and 51%, respectively (Fig. 17A). All mutants discussed were 
expressed on the surface at or near WT levels (Fig. 17B). Thus, these mutants represent 
additional residues in the fusion loops that are critical for gB function. The remaining 
mutants, representing four charged residues and one hydrophobic amino acid, functioned 
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A 
Fusion Activity of gB Fusion Loop Mutants 
B Surface Expression of gB Fusion Loops Mutants 
Figure 17. Ability of gB fusion loop mutants to be expressed on the cell surface of CHO cells 
and function in cell-cell fusion. (A) cELISA was used as a measure of cell surface expression of gB 
mutant proteins in CHO ceils. Effector cells (cells transfected with plasmids encoding T7 polymerase 
along with plasmids encoding gD, gH, gL, and either WT gB or the indicated gB mutant) were seeded 
into 96-well plates and transfected in parallel with those for the fusion assay. Expression of the 
indicated gB mutant on the cell surface was detected using PAb R69. (B) CHO cells stably expressing 
HVEM (CHO-HVEM12) were transfected with a plasmid encoding the luciferase gene under the control 
of the T7 promoter and cocultivated with effector cells. The cells were lysed and assayed for luciferase 
activity as a measure of cell-cell fusion. The luciferase value for the empty vector was subtracted 
(background), and all data are represented as percentages of WT activity. Each experiment was 
performed in triplicate. The data and standard deviations were derived from a minimum of three 
experiments. 
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between 60% and 100% of WT levels of fusion. I suggest that these five residues (HI77, 
R178, R258, E260, & Y265) play a limited role in gB function. Previously, V259R and 
W174K were discarded because they failed to be expressed on the surface. I cannot 
make any conclusions about F262 and its possible role in fusion because F262D is only 
expressed on the surface at 30% of WT levels. All data are summarized in Table 2. 
Mutant gB Proteins are Conformationally Correct 
To determine if functionally impaired gB mutant proteins were properly folded, I 
immunoprecipitated the mutants, F175K, G176K, H263A, and R264A, from transfected 
cell extracts with mAbs DL16, SS55, and SS145. Each of these mAbs reacts against a 
distinct conformational epitope (Fig. IOC) (7). Additionally, SS55 has strong virus-
neutralizing activity and recognizes an epitope that includes domains I and V. Thus, I 
rationalized that its binding gB may be particularly sensitive to structural changes caused 
by the mutations. SS145 recognizes an epitope in domain IV. Because all fusion proteins 
function as a trimer; I tested whether the mutations in gB affected trimerization using the 
trimer specific mAb DL16. Anti C-myc was used as a negative control. All mutants were 
immunoprecipitated by DL16, SS55, and SS145. None of the gB proteins were 
immunoprecipitated by the a C-myc mAb (Fig. 18). These data indicate that for the four 
most impaired mutants, all three epitopes were intact and none of the mutations prevented 
trimerization. Those mutants that functioned like WT gB were not tested by 
immunoprecipitation. 
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Figure 18. gB Mutant proteins are correctly folded. gB mutant proteins were 
immunoprecipitated from lysates of transfected L cells using MAbs DL16 (lanes A), 
SS55 (lanes B), or SS145 (lanes C) against conformational epitopes. A mAb against 
c-Myc was used as a negative control (lanes D). gB mutations are indicated at the 
tops of the Western blots. WT gB is expressed from pPEP98. PAb R69 was used for 
detection of gB. Molecular weight markers are labeled on the left in thousands. 
Complementation ofHSVgB Null Virus with Fusion Loop Mutants 
HSV glycoprotein mediated cell-cell fusion is used as a surrogate for virus-cell 
fusion. Another way to test the function of gB mutant proteins is to incorporate them into 
an HSV strain lacking the gB genes and test the ability of the complemented viruses to 
enter cells. In my previous study I had not used this assay. Therefore, I carried out the 
complementation experiments on seventeen mutants that represented thirteen of the 
fourteen amino acids in the fusion loops. I omitted V259R because it was misfolded, but 
included F262D because it did exhibit some cell surface expression (Fig. 15B). Vero cells 
were transiently transfected with one of the mutant gB constructs and 24 h later they were 
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infected with HSV-1 (K082), a virus strain that lacks the gB ORF, and that was 
phenotypically complemented with WT gB to allow for entry (19). Progeny virions 
containing the transfected mutant gB were harvested 24 hours post-infection and 
quantitated by a plaque assay on gB complementing VB38 cells (Fig. 19) (52). 
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Figure 19. Ability of fusion loop mutants to complement entry of a gB 
null HSV virus. Vero cells were transfected with plasmids encoding gB 
mutants, incubated overnight, and infected with gB-null HSV that had been 
phenotypically complemented with wild-type gB to allow for entry. Cell lysates 
containing progeny virions complemented with the gB mutants were 
harvested and assayed for virus entry into gB expressing VB38 cells. After 2 
days of incubation at 37°C, cells were stained and plaques were counted. 
Titers are expressed as % of PFU/ml of virus complemented by WT gB. The 
data and standard deviations errors were derived from a minimum of three 
experiments and the figure represents a compilation of all the data. 
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I considered a mutant to be severely impaired for virus entry when the titer was 
20% of WT or less. I evaluated a total of thirteen residues in the fusion loops (all except 
V259). Only six mutants (H177A, R178A, R258A, E260A, F262L, & Y265R) were 
above 20% of the WT level of complementation (Fig. 19). All of the remaining mutant 
viruses were severely impaired (less than 20%) or non-functional. The data for 
complementation correlated well with the fusion data (Fig 17A). Interestingly, three 
residues that are important for gB function (F175, H263, R264) cluster together just 
outside the hydrophobic ridge that is critical for (72) and (chapter III). All cell-cell 
fusion and complementation results of this study, and my previous one are summarized in 
Table 3. 
Secreted gB Mutants were Produced 
I hypothesize that the two domain I loops are membrane interacting elements that 
insert into target membranes. Mutations in the fusion loop of E and El that impaired 
fusion also impaired liposome association (1, 84). Using these studies as a guide, I 
tested four gB mutants in several functional assays with the goal of determining the 
mechanisms fusion inhibition. The mutants were expressed as truncated, secreted 
proteins using a baculovirus expression system and were examined for their ability to 
insert into target membranes, block virus entry, and bind cells. 
These proteins, each with a single point mutation in the secreted gB730t were: 
gB730t-W174R, gB730t-Y179S, gB730t-H263A, and gB730t-R264A. Each protein was 
purified by affinity chromatography, using the trimer specific mAb DL16. Silver stains 
of an SDS-PAGE gel (Kindly done by Huan Lou in our lab) showed that all of the mutant 
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Mutant Fusion Surface 
Loop Expression 
Fusion Complementation 
(% WT) 
CELISA 
(% WT) 
Luc. 
(%WT) 
Syncyti 
WT 100 100 100 
W174Y 
W174R 
W174K 
F175K 
G176K 
H177A 
R178A 
Y179S 
Y179K 
R258A 
V259R 
E260A 
A261W 
A261D 
A261D/W174 
F262L 
F262D* 
H263A 
R264A 
Y265R 
II 
II 
II 
II 
l& l l 
II 
II 
II 
II 
II 
123 7- 47 
146 7-57 
55 7- 23 
110 7-19 
92 7-16 
84 7-19 
68 7-17 
142 7-45 
100 7-25 
91 7- 22 
22 7-22 
85 7-14 
108 7-60 
125 7-50 
162 7-10 
105 7-59 
30 7-18 
95 7- 20 
64 7- 5 
82 7-22 
46 7-14 
9 7-14 
0 
26 7- 5 
0 
63 7- 7 
83 7-10 
0 
0 
81 7-11 
0 
74 7-14 
18 7-16 
9 7-8 
0 7-10 
68 7- 21 
0 
51 7-9 
31 7- 4 
93 7-17 
-
-
-
N/T 
N/T 
N/T 
N/T 
-
-
N/T 
-
N/T 
-
-
-
+ 
-
N/T 
N/T 
N/T 
4.9 7- 2.8 
0.2 7- 0.2 
N/T 
0.4 7- .42 
0 
46 7-13 
30 7-15 
0 
0 
72 7-15 
N/r 
72 7-12 
0 
0 
N/T 
27 7- 8.1 
0 
12 7-.97 
19 7-17 
44 7- 6.8 
Table 3. Properties of all gB Fusion Loop Mutants. Data from 
figs. 13, 15, & 17 have been compiled in this table for comparison. 
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Fiqure 20. Truncated forms of qB mutant proteins exi 
system are expressed and folded correctly. (A) Four gB mutants the point 
mutations, Y179S, W174R, H263A, and R264A were cloned and expressed in a 
baculovirus expression system as secreted forms each truncated after amino acid 
730. Proteins were visualized by silver stain and B) detected with R69 and visualized 
by western blot. (C) The gB mutant proteins were immunoprecipitated using MAbs 
DL16 (lanes A), SS10 (lanes B), SS55 (lanes C), or C226 (laneD) against 
conformational epitopes. Anti c-Myc was used as a negative control (lanes D). gB 
mutations are indicated at the top of each Western blot. WT gB was expressed from 
pPEP98. PAb R69 was used for detection of gB. Molecular weight markers are 
indicated on the left in kd. 
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gB proteins migrated as two major bands like WT gB, but there were some minor 
differences (Fig 20A). Some bands migrated slightly faster than others. The purified 
proteins were tested for proper folding by immunoprecipitation using mAbs DL16, SS10, 
SS55 and C226. Of these four, all neutralize virus except for DL16. SS10 recognizes the 
same epitope in domain IV that is recognized by SS145 (Fig. IOC) and C226 recognizes 
an epitope in domain II (7). All of the mutant proteins reacted with each of the a-gB 
mAbs (Fig. 20B). The a c-myc control antibody recognized none of the gB proteins. 
These data suggest that all of the secreted mutant proteins are antigenically correct at four 
distinct epitopes and three functional regions (7). 
Mutant gB Proteins are Impaired in Liposome Binding 
Previously, others in our laboratory showed that HSV binds liposomes (PC:Chol) 
when incubated with the gD receptor, HVEM, at pH 5.0 and 37° C (180). In addition, 
they showed that of the proteins in the HSV fusion complex (soluble forms of gD, gH/gL, 
and gB), only gB730t binds lipid rafts (9). This work suggested that HSV may be 
interacting with lipids through gB, the suspected fusogen. Work with TBEV E and SFV 
El showed that mutations in their fusion loop impair liposome association (1, 84). 
Therefore, I hypothesized that if gB inserts into target membranes via the putative fusion 
loops, then the soluble forms of the fusion loop mutants should be impaired in liposome 
binding. 
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B Liposome Floatation of gB Mutants 
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Figure 21. Mutations in the gB putative fusion loops impair liposome 
binding. (A) Liposome floatation was optimized using NBD-labeled liposomes. 
The gradient was fractionated and adjusted to . 1 % NP-40. Liposomes 
migrated to the top of our gradient. The majority were located in fraction 1 and 
a minority were located in fraction 7. (B) WT gB730t and the four fusion loop 
mutants were incubated with unlabeled liposomes for 1 hr at 37 °C, adjusted to 
1M KCL and incubated at 37 °C for an additional 15 mins and layered 
beneath a discontinuous 5 - 40% sucrose gradient. Gradients were 
fractionated and adjusted to .1 % NP40. Only fractions 1, 4, and 7 are shown. 
Samples were analyzed in duplicate by capture ELISA using SS145 to capture 
gB and R69 to detect it. (C) To support the ELISA as a valid readout, all 
seven fractions of the WT and Y179S gradients were electrophoresed, western 
blotted, and probed with R69. 
Liposome association can occur through superficial electrostatic interactions or 
through more stable interactions typical of proteins hydrophobically anchored into the 
membrane (44). Incubation of the liposome-protein mixture with high salt (1M KCL) 
inhibits these electrostatic interactions. Therefore proteins that associate with liposomes 
under these conditions likely do so as a result of membrane insertion. Initially, I tested 
binding of gB730t to liposomes in the absence of high salt. When I repeated this with 
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1M KCL, I found that gB730t exhibited an enhanced ability to associate with liposomes, 
suggesting that it is inserted into the liposomes (data not shown). Therefore, I evaluated 
the mutant gB proteins for liposome binding in the presence of 1M KCL. Each of the 
mutant forms of gB as well as WT gB730t were incubated with liposomes at 37°, pH 7.4, 
for 1 hour. The mixture was then adjusted to 1M KCL and incubated at 37° for an 
additional 15 min. Each mixture was placed in a tube, overlaid with a 5% to 40% 
discontinuous sucrose gradient and centrifuged. To track liposome flotation, I spiked a 
liposome sample with 5% NBD-PC. Most of the fluorescent liposomes floated to the top 
of the gradient (Fig. 21 A). I used ELISA to quantify gB in each fraction, using mAb 
SS145 (binds domain IV, Fig. IOC) to capture gB and pAb R69 for detection. 
Approximately 40% of WT gB730t was located in fraction 1 (top), small portions 
were in the middle (quantitated for fraction 4), and about 50% was in fraction 7 (bottom) 
(Fig 2IB). When liposomes were absent, all of gB was in fraction 7 (not shown). In 
contrast, none of the mutant forms of gB730t associated with liposomes. Thus, gB730t-
W174R, gB730t-Y179S, gB730t-H263A, and gB730t-R264A were located almost 
exclusively in fraction 7 (Fig. 21B). As an additional test, I examined samples of the 
gradient fractions for WT gB730t and gB730t-Y179S by western blot (Fig 21C). WT 
gB730t was found in fractions 1, 6 and 7, but gB730t-Y179S was only in fraction 7. 
These results support my hypothesis that the domain I loops are fusion loops as mutations 
at four different positions ablated liposome binding by gB. In addition, since neither 
gB730t-R264A nor gB730t-H263A floated with liposomes, my results suggest that some 
charged residues are necessary (in addition to the hydrophobic residues) for target 
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membrane insertion by gB. Thus, I suggest that loss of target membrane insertion is one 
possible mechanism of fusion inhibition by these mutants. 
Mutant gB Proteins Engage the Unknown gB Receptor Like WT 
Dr. Florent Bender, in our lab, previously showed that gB730t blocks HSV entry 
into Gro2C cells (8). Because gB binds HSPG, little blocking function is detected on 
Vero cells, in the presence of HSPG. When tested on L cells, gB blocks entry with about 
half the molar efficiency of gD. When tested on Gro2C cells, L cells deficient in HSPG 
expression, gB blocks entry of HSV with similar efficiency as gD suggesting that gB 
binds a non-heparan sulfate HSV receptor (8). Recently PILRa has been identified as a 
gB receptor (153). It is possible that domain I of gB binds a proteinaceous cell surface 
receptor and that fusion loop mutants are unable to function in fusion because they no 
longer recognize this receptor. If true, the soluble fusion loop mutants should be 
impaired in their ability to block virus entry into cells. 
To test this in a blocking assay, I plated Gro2C cells in a 96-well plate at 80% 
confluency. Decreasing equimolar concentrations of WT or mutant gB were added for 30 
min at 4° C. HSV-1 tkl2, which expresses P-gal under the immediate early promoter, 
was added at an MOI of 10 for lh at 4° C. The virus-cell mixture was shifted to 37° C, 
incubated for 6h, and infection was quantified by P-galactosidase expression. 
Each of the mutant gB proteins blocked entry of virus as well as WT gB730t (Fig 
22A). At a concentration of 5 uM , both the WT and mutant gB proteins inhibited entry 
by 70 - 90%. These data suggest that the fusion loops of gB730t do not participate in 
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Figure 21. Mutations in the gB putative fusion loops impair liposome 
binding. (A) Liposome floatation was optimized using NBD-labeled liposomes. 
The gradient was fractionated and adjusted to . 1 % NP-40. Liposomes 
migrated to the top of our gradient. The majority were located in fraction 1 and 
a minority were located in fraction 7. (B) WT gB730t and the four fusion loop 
mutants were incubated with unlabeled liposomes for 1 hr at 37 °C, adjusted to 
1M KCL and incubated at 37 °C for an additional 15 mins and layered 
beneath a discontinuous 5 - 40% sucrose gradient. Gradients were 
fractionated and adjusted to . 1 % NP40. Only fractions 1, 4, and 7 are shown. 
Samples were analyzed in duplicate by capture ELISA using SS145 to capture 
gB and R69 to detect it. (C) To support the ELISA as a valid readout, all 
seven fractions of the WT and Y179S gradients were electrophoresed, western 
blotted, and probed with R69. 
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binding to a receptor, as the mutants are not impaired in this function. Future studies may 
test this more directly with PELRa. 
Mutant gB Proteins are Impaired in Cell Binding 
Thus far, I have validated impaired target membrane insertion and eliminated loss 
of receptor binding as possible mechanisms for inhibition of gB dependent fusion by 
fusion loop mutants. Next, I tested the ability of the gB mutant proteins to bind Gro2C 
cells. I expected them all to bind to cells as effectively as WT gB 730t since they 
blocked virus entry. However, mAbs (SS55 and SS10) which represent two distinct 
functional regions, block binding of WT gB730t to cells (7, 8). Although it is possible 
that both mAbs block binding of gB730t to a cell surface receptor, it is also possible that 
they block binding of gB730t to two independent moieties. Decreasing equimolar 
concentrations of WT g or mutant gB were added to monolayers of Gro2C cells for lh at 
4° C, washed, and fixed in 3% PFA for 10 min. Cell-based ELISA was used to detect gB 
binding (Fig 22B). 
Unexpectedly, all of the mutant proteins were impaired in their ability to bind 
Gro2C cells to various extents. At 5 uM, W174R bound cells at 62% of WT. R264A 
bound at 51%, H263A bound at 31%, and Y179S bound at 22% of WT levels. These 
surprising results suggested to me that liposome binding and cell binding may depend on 
a common function of gB that does not involve binding to an entry receptor. Although 
gB is known to bind HSPG, this moiety is absent on Gro2C cells. Interestingly, one of 
the mAbs that blocks binding of gB730t to cells, SS55, recognizes an epitope near the 
fusion loops (Fig. IOC) (7). These results suggest several possibilities. Perhaps gB 
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interacts with a cell surface lipid during fusion and this interaction is dependent on fusion 
loop integrity. It seems likely that SS55 blocks binding of gB730t to cells through an 
interaction that impairs fusion loop function. Alternatively, insertion of the gB730t 
fusion loops into the cellular membrane may account at least in part for the observed cell 
binding. If this is the case, it would suggest that as much as 70% of the detected binding 
of WTgB730 to Gro2C cells involves an interaction between the fusion loops and a lipid. 
Because the mutants are impaired for cell binding, one interpretation is that binding of gB 
to a cell surface lipid is an aspect of its normal function in fusion. However, such as 
conclusion must carry the caveat that gB730 lacks the downstream hydrophobic domains 
that are also part of the ectodomain and therefore interactions between the fusion loops 
and the cell membrane could be an artifact of the fusion loops being exposed by this 
truncation. 
Heterologous Interactions ofgB Fusion Loop Mutants with gH/gL 
In collaboration with Dr. Atanasiu, in our lab, we used bimolecular 
complementation (BiMC) to examine the ability of gB fusion loop mutants to interact 
with gH/gL in a fusgenic environment. Previously, we used BiMC to show that gB 
interacts with gH/gL in receptor bearing cells when gD is added in trans as a soluble 
protein (gD306). This interaction occurred concurrently with cell-cell fusion (2). If 
gD306 was omitted, there was no interaction between the tagged forms of gB and gH/gL 
and no fusion. Perhaps my gB fusion loops mutants failed to function in fusion because 
they could no longer interact with gD or gH/gL. 
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Here, to test this notion, we asked whether mutations to the gB fusion loops alter 
the interaction between gH/gL that occurs in response to gD/ receptor binding. For this 
purpose Dr. Atanasiu tagged the full-length mutant gB proteins, Y179S, W174R, and 
A261D at the C-terminus C-terminal half of EYFP (Venus) to create Be*174, Be*179 and 
Be*261. CIO cells were transfected with Hn, gL and Be (WT or mutants). At 20 h post-
transfection, fusion was triggered by the addition of soluble gD306. Cells were examined 
by confocal microscopy for restoration of EYFP fluorescence in the green channel; 
glycoprotein expression was monitored in the red channel by using R137 gH Pab (Fig. 
23) or A22+SS55 gB Mab (not shown). 
In the absence of gD, neither wild-type nor mutant gB interacted with gH/gL, as 
seen by the lack of EYFP complementation. When fusion was triggered by the addition 
of gD306, green syncytia were observed in cells transfected with gL, Hn and wild type 
Be, confirming the previous observations (72). However, no fusion occurred when WT 
Venus tagged gB was replaced by any one of the fusion loop mutants (Be*174, Be*179 and 
Be* ), consistent with my previous results with the untagged forms of these gB mutants 
(72). Of most interest was the observation that, none of these mutant gB proteins 
interacted with Hn/gL; instead we observed only background levels of green fluorescence 
in the unfused cells. 
This result was somewhat surprising and suggests that the interaction between gB 
and gH/gL requires fusion loop integrity. (Brian I fail to see how this interaction with gD 
is a control -1 think it confuses rather than enlightens) There are several possible 
explanations for the results. First, it is possible that gB must interact with gH/gL in order 
for gB to insert into the target membrane to begin fusion. However this seems unlikely 
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Figure 23. Full-length Fusion Loop Mutants Fail to Interact with gH/gL 
by BiMC. When fusion was triggered by the addition of gD306 to cells 
transfected with gl_, Hn and WT Be, green syncytia formed (top panel). When 
Be was substituted with fusion loop mutants (Bc*174, Bc*179 and Bc*261) no 
syncytia formed and only background green fluorescence was observed 
(bottom three panels). C10 cells were transfected with Hn, WT Be or the 
indicated mutant Be for 20 h, fixed, and stained with the anti-gHpAb R137. All 
were analyzed by immunofluorescent assay for protein (red) and YFP (green). 
Confocal images were captured at 100X magnification and all images were 
captured by using the same camera setting. 
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since gB730t inserts in the absence of gH/gL. Second, it is possible that gB is first 
inserted into the target membrane in response to gD/receptor binding, and this is followed 
by an interaction with gH/gL. Thus, loss of gB interaction with gH/gL could be another 
mechanism by which mutations to the gB fusion loops inhibit gB dependent fusion. 
DISCUSSION 
HSV gB has been proposed to be a viral fusion protein that inserts into the target 
cell membrane through its fusion loops. One goal of this study was to further define the 
functional architecture of the gB fusion loops. I mutated every residue in the gB fusion 
loops and evaluated their importance in gB function. 
The Contribution of the Hydrophobic Ridge Formed by the gB Fusion Loops 
The crystal structures of class II and VSV fusion proteins in their post-fusion 
states as well as functional data have identified the fusion loops of these proteins (1,15, 
45, 55, 68, 99, 143,145, 170). It is hypothesized that aromatic amino acids (W, Y, and F) 
are paramount in their function, and it is presumed that their side chains, along with their 
carbon backbones, are inserted into the target membrane (120,142,145). I have 
designated the HSV-1 gB putative fusion loops as amino acids 174-179 and 258-265 (14 
in total) based on their structure, position, and biochemical nature of the residues. 
Several amino acids form a surface exposed hydrophobic ridge that I hypothesize is 
inserted into the target membrane (Fig. 24). Two groups of mutants were generated to 
evaluate the role of all fourteen individual residues in gB dependent fusion. The first 
group I focused on consisted of the residues that form the hydrophobic ridge at the base 
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of domain I of gB. Substitution of these hydrophobic amino acids to charged ones 
(W174R, G176K, Y179K, and A261D) completely abolished function in cell-cell fusion 
Figure 24. Model of gB fusion loop insertion into the target 
membrane. A) I propose that two groups of residues within the fusion 
loops, the hydrophobic ridge (blue) and two charged residues (red), 
function in membrane insertion. B) I suggest the hydrophobic ridge, 
formed by the two fusion loops, inserts into the target membrane in a 
local conformation different from that solved by Heldwein et. Al 2006. In 
addition, I propose that H263A & R264 work in concert with the ridge by 
stabilizing or orienting its insertion by interacting with polar head groups 
on the periphery of the membrane. 
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(Fig. 17) and virus entry (Fig. 19) (less than 10% of WT in both assays). Thus, I showed 
that these residues are critical for gB function in fusion. Similar studies in EBV gB, 
VSV, and VSHV support these data (4,143, 170). V259 and F262 are also in his ridge 
and I propose that they are also important. However, when they were substituted with 
charged residues, the proteins were misfolded. Thus, I could draw no conclusion about 
their role. In future studies, I suggest that they be mutated to a different amino acid, e.g. 
serine. 
In my second study, I evaluated all of the residues in the loops that lie outside of 
the hydrophobic ridge (Fig. 16E). Six charged residues (H177A, R178A, R258A, 
E260A, H263A, R264A) were substituted with alanine and two aromatic residues 
(F175K and Y265R) were substituted with charged residues. My data suggest that five 
play only minor roles on their own, but that F175, H263, and R264, are very important in 
gB function. F175K, H263A, and R264A functioned at 26%, 51% and 31% of WT in 
cell-cell fusion, respectively. F175K was unable to mediate virus-cell fusion (0.4%). 
H263A and R264A functioned at 12% and 19% of WT, respectively, in virus-cell fusion 
(Fig 17). 
Thus, of fourteen residues evaluated, seven are critical for function of gB in cell-
cell fusion (Fig. 17) and virus entry into cells (complementation, Fig. 19). Five others 
play more minor roles on their own and data for two is inconclusive. I separated the 
critical residues into two groups based on their position in the crystal structure and the 
severity of the defects of the corresponding mutant(s). The first group includes W174, 
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G176, Y179, A261, and F262 that I propose to be directly inserted into the target 
membrane. The second group includes the charged residues, H263 and R264 and the 
hydrophobic amino acid F175. The mutant F175K was impaired in functional assays, but 
it is difficult to imagine how it can insert into a membrane based on its position in the 
solved structure. This is discussed in more detail below. 
Fusion Loop Architecture 
As mentioned above, W174, G176, Y179, & A261, form a hydrophobic ridge that 
likely is inserted into the outer layer of a target membrane. Three other amino acids, 
H263, R264, and F175 are all adjacent to the ridge. All are important and it is logical to 
assume that the two charged amino acid play a supporting role. However, F175 is more 
difficult to understand. In cell-cell fusion (Fig. 17), F175K function (26%) was more 
comparable to that of R264A (31%) than the mutant W174R ( 9%). Conversely, in virus-
cell fusion (Fig. 19) F175K function (0.4%) was more comparable to W174R (0.2%) than 
to R264A (19%). These data are summarized in Table 2 (chapter IV). If F175 were 
inserted into the target membrane, the mutant form should have been more impaired in 
cell-cell fusion. However, F175 connects W174 and G176 and a rotation of either phi 
angle of the carbon backbone would reposition the sidechain closer to the hydrophobic 
ridge. I hypothesize that F175 may be in this position in the prefusion form of gB. 
It is interesting that the mutants A261D and G176K were non-functional in cell-
cell fusion. Although it appears that their side chains are not long enough to be inserted 
into a target membrane, I suggest that the backbone of these residues must be inserted. 
Similarly, mutation of VSV G A177 to K abolished fusion activity (Fig. 6B in green) 
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(55). At this time it is still unclear what role alanine and glycine residues play in the 
function of fusion peptides. However they are commonly found in, and are often 
indispensable, for the function of either classical fusion peptides or fusion loops (110). I 
hypothesized that an increase in hydrophobicity of the fusion loops would enhance 
fusion. Somewhat surprisingly, the substitution of a tryptophan for alanine at position 
261 did not enhance cell-cell fusion. Tyrosines and tryptophans are commonly found at 
the interface between fatty acid chains and head-group layers of lipids (185), therefore it 
was interesting to find that the mutant A261W made gB completely non-functional in the 
virus entry assay. Interestingly, structural data suggest that W174 and Y179 likely insert 
deeply into membranes since they protrude furthest from the center of the ridge. It was 
surprising to me that the mutations to charged residues had as severe an affect on 
liposome binding by gB as did mutations to aromatic residues. These data suggests that 
charged residues play a different, albeit important, role in fusion loop function since they 
are unlikely to be able to insert into a membrane. Our work supports the notion that 
position and orientation of a viral fusion peptide within the fusion site is at least as 
important as its hydrophobicity and secondary structure (110). Thus, position and 
context of specific amino acid side chains are paramount in optimal fusion loop function. 
I suggest that charged residues in the fusion loop participate in fusion by positioning 
and/or stabilizing insertion of the fusion loops through interactions with lipid head-
groups on the cell surface. 
Mechanisms of Fusion Inhibition by Mutations to the gB Fusion Loops 
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I prepared four different soluble recombinant gB proteins, each carrying one of 
the critical mutations. gB730t-W174R, gB730t-Y179S, gB730-H263A, and gB730t-
R264A were all expressed folded correctly (Fig. 20). I tested these mutant proteins for 
their WT function in binding liposome model membranes (Fig. 21), engaging a putative 
gB receptor to block virus entry (Fig. 22A), in cell binding (Fig. 22B). In addition, 
fusion loop mutants in the full-length gB were tested for function in interaction with 
gH/gL. 
I showed by co-flotation experiments that, in the presence of 1M KCL gB 
associates with liposomes. This suggest that WT gB730 inserts into liposome model 
membrane. All of the mutants were impaired in liposome binding, emphasizing the 
importance of these hydrophobic and charged amino acids for membrane insertion. This 
data provides some of the strongest evidence to date that the gB domain I loops function 
in target membrane insertion. Also, it very likely that target membrane insertion is an 
obligate step in HSV entry and cell-cell fusion. Thus, loss of the ability to insert into 
target membrane is one explanation for the impairment of gB dependent fusion by fusion 
loop mutations. 
In contrast, I found that the mutant forms of gB blocked entry as well as WT gB 
(Fig. 22A). Assuming that blocking of entry is due to competition for a cell surface 
receptor of virion gB. I suggest that fusion loops have no role in receptor binding, and 
that the receptor binding domain is structurally distinct from the fusion loops. Thus, it is 
unlikely that receptor binding has a role in inhibition of HSV fusion by the gB fusion 
loop mutants. 
85 
To my surprise, all of these mutants were impaired in their ability to bind to 
Gro2C cells (Fig.22B). Clearly, cell binding is dependent on fusion loop integrity. This 
seeming contradiction leads me to believe that they bind to a lipid moiety on cell 
membranes that is distinct from a proteinaceous gB receptor. My data suggests that as 
much as 70% of the binding of gB to Gro2C cells could be through gB-lipid interactions. 
Thus, impairment of cell binding could be a mechanism by which mutations to the gB 
fusion loops impair HSV entry and gB dependent fusion. Liposome association and cell 
binding are both impaired by loss of fusion loop function. Specific interactions of VSV 
G with negatively charged phospholipids (37) and of SFV El with cholesterol (175) are 
thought to be essential for the entry of their respective viruses into cells. Interestingly, 
our liposomes are composed of phosphatidylcholine (slight negative charge) and 
cholesterol. SS55 recognizes an epitope near the fusion loops (Fig. IOC) and blocks 
binding of WT gB730t to cells (7, 8). Perhaps future studies will use this mAb to dissect 
the importance cell binding via gB-lipid interactions in HSV entry. 
Recently, our laboratory showed that gB interacts with gH/gL when fusion is 
triggered by binding of soluble gD to a cell surface receptor. This was done using a 
bimolecular complementation assay. In collaboration with Dr. Doina Atanasui in our 
laboratory, we found that tagged forms of gB, Y179S, W174R, and A261D, were unable 
to interact with gH/gL in the presence of gD and receptor. These results suggest that this 
interaction is dependent on gB fusion loop function. This is the third potential 
mechanism for inhibition of HSV fusion by gB fusion loop mutants. These results 
suggest that insertion of gB into the target membrane not only precedes fusion, but also 
precedes its interaction with gH/gL. 
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Thus we have shown that gB fusion loop mutants are impaired in membrane 
insertion, cell binding, and interaction with gH/gL. All three could potentially be 
explanations for the loss of gB dependent fusion and HSV when the gB fusion loops are 
mutated. It is even possible that all three functions have a temporal relationship. There is 
precedence for the necessity of specific protein-lipid interactions prior to insertion of a 
fusion loop into the target membrane, which precedes subsequent conformational 
changes and fusion. The conformational change that reorganizes SFV El from a 
heterodimer with E2 to a homotrimer is dependent on insertion into the target membrane, 
which requires specific interactions with cholesterol and the presence of sphingolipids in 
a low pH environment (175). 
Models 
I put forth two models. First, I suggest that the gB fusion loops function as a 
structural unit through a concerted effort between the hydrophobic and charged residues 
(Fig. 24A). I suggest that the hydrophobic ridge inserts into the target membrane and that 
charged residues in the loops, primarily H263 and R264, interact with phospholipid head 
groups but do not penetrate the hydrophobic core (Fig. 24B). I propose that this 
interaction likely guides and stabilizes insertion of the hydrophobic ridge into the 
hydrophobic core of the bilayer. It is unclear if gB binds cells via the fusion loops during 
entry. It is possible that insertion of the soluble truncated protein into the cell membrane 
is measurable as cell binding, but that it is an artifact resulting from deletion of the two 
hydrophobic regions upstream of the TM domain. 
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Secondly, I suggest a model for HSV fusion (Fig. 25) in which the initial attachment is 
mediated by gB and gC as previously described (75,155). Glycoprotein D receptor 
binding sends an activation signal, possibly in combination with low pH and/or a 
gB/receptor interaction, to pre-fusion gB. This signal triggers a conformational change in 
gB, converting it into a membrane interacting intermediate that can only form as gB 
inserts into the target membrane. This would be a necessary step, and I propose that it 
precedes the interaction between gB and gH/gL that results in membrane fusion. I 
propose that this necessitates the final structural transition of gB into the classical hairpin 
structure found in post-fusion class I and II fusion proteins, and along with gH/gL drive 
membrane fusion. 
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gH/gL 
virus membrane 
Figure 25. Proposed Model for HSV Fusion. A) gB and gC (omitted for simplicity) facilitate the 
initial attachment through interaction with HSPG on the cell surface. B) gD then engages one of 
three cell surface receptors and undergoes a conformational change that opens up the structure, 
displacing the C-terminus, in red, and allowing the "pro-fusion" domain, loop in red, to communicate 
an activation signal to gB. C) gB, shown as a monomer for simplicity, undergoes a conformational 
change that exposes the fusion loops to the target membrane where they possibly bind cell surface 
lipids and likely insert into the membrane. D) Mutations to the fusion loops that abrogate fusion are 
impaired in cell binding, target membrane insertion, and interaction with gH/gL. E) If gB properly 
interacts with target membrane, subsequent conformational changes occur that facilitate an 
interaction with and drive fusion in concert with gH/gL. In A) - D) The ribbon representation of the 
VSV G crystal structure is used to represent HSV gB. In E) The ribbon representation of the crystal 
structure of gB is colored to match VSV G. Figure is adapted from Heldwein et al 2008. 
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Future Directions 
My work has done much to shed light on how gB functions and the role it has in 
HSV fusion. However, this is only a snapshot in the complex process of HSV fusion. 
Many questions remain in regards about how gB functions in HSV entry. Above, I 
suggest that gB binding to a cell surface lipid molecule is detectable as cell binding. Can 
specific lipid moieties block soluble gB binding to cells? Is this a property of full-length 
gB, before and/or after activation by gD? Cell binding of gB can be blocked by SS10 and 
SS55, mAbs that recognize epitopes in domain IV and domain I, respectively (Fig. IOC) 
(7, 8). Do these mAbs recognize epitopes near two distinct binding regions, or are 
domains IV and I located near one another in the pre-fusion form of gB? It is possible 
that many of these questions can be answered using our biochemical and functional 
assays. But, a pre-fusion structure of gB will be another huge step forward in 
understanding this protein. 
My work in collaboration with Dr. Atansiu suggests that gD communicates an 
activation signal to gB. How is this signal communicated through the "pro-fusion" 
domain and how does it "activate" gB to undergo the conformational changes that lead to 
fusion? It seems as if my gB mutants in the context of full-length gB cannot progress 
into the membrane interacting intermediate and beyond. It is generally accepted that gB 
binds a receptor and this receptor has been suggested to be PILRa (153). More data are 
needed to support this report. Is this gB receptor obligatory for HSV entry, or does it 
depend on the entry pathway? Does it bind directly to gB730t? Is it cell type dependent, 
and is it the only receptor for gB? Also, where on the gB structure is the receptor binding 
domain? 
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Our work suggests that gH/gL plays in indispensable role, downstream of the 
formation of the gB membrane interacting intermediate. What might this role be? One 
noticeable difference in the post-fusion structure of VSV G and HSV gB is that gB has no 
obvious 6HB. Neither G nor gB is metastable, which suggest that these proteins have 
less potential energy than class I and class II proteins. G must presumably accomplish 
membrane fusion only through the cooperation with other G molecules. Perhaps gB 
cooperates with gH/gL to generate enough energy to drive membrane fusion. Heptad 
repeats and membrane interacting elements have been predicted in gH, both of which are 
features of other fusion proteins (64, 65). It is possible that gH/gL and gB together form 
a 6HB. However, since this would be a very stable structure, I would have expected such 
a complex to have been detected in prior studies using co-immunoprecipitation. Surely, a 
gH/gL structure will do much to shed light on its role in HSV fusion. 
Final Thoughts 
VSV G has been shown to bind specifically to negatively charged lipids in 
necessary steps during fusion (37) and SFV must bind cholesterol in order to insert into 
the target membrane (175). Perhaps gB also binds lipids in a step that precedes 
membrane insertion. It must be noted that full-length gB has two hydrophobic segments 
before the transmembrane anchor that are missing in the form used in this study. It is 
possible the fusion loops are normally masked by these hydrophobic segments, and are 
revealed to bind lipids and insert into a target membrane at a very specific stage of 
fusion. 
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It will be interesting to see if my findings will be applied to fusion loops in 
proteins that belong to viruses both in and outside the herpesviridae. Structurally, the 
fusion loops of gB seem sub-optimal for membrane insertion (76). This structural 
arrangement presented a more complex view of the gB loops than in other proteins where 
a couple of residues stretch down beyond the rest of the loops. Instead of defining the gB 
fusion loops as just those aromatic residues that would seemingly be inserted into the 
membrane, I asked whether or not each of the fourteen residues in this region had a role 
in fusion. In doing so, I uncovered unexpected evidence that charged residues, in some 
aspects, are just as important as aromatics in fusion loop function. 
These data led to further observations that suggest, in addition to inserting into target 
membrane, fusion loops may play a large role in cell membrane binding. To my 
knowledge, this is a novel concept. gB binding to its receptor was only a minor portion 
of the measurable gB cell binding. Could the fusion loops of fusion proteins in other 
viruses be as important in cell binding? Is this a mechanism the virus uses to either 
traffic to or to recruit the appropriate membrane microdomain? If the pre-fusion, full-
length form of gB does not bind cells using the fusion loops, could this be a mechanism 
the virus uses to get to the appropriate microdomain in the endocytic membrane? 
Overall, my work suggests that fusion loop function is much more complex than a simple 
model whereby only aromatic residues insert into a membrane to anchor the protein and 
destabilize the membrane. It seems as if this insertion is essential for additional reasons. 
It is noteworthy that mutations in the cytoplasmic domain of gB can cause syncytial 
phenotypes, thus acting far away on the ectodomain. I suggest that when the gB fusion 
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loops are inserted, this may affect other regions of gB. It is my hope that this work will 
be important in the understanding of HSV and viral fusion. 
CHAPTER V. APPENDIX: STRUCTURE-BASED MUTAGENESIS OF GB 
CROWN 
RATIONALE 
Recent advances have presented many structural insights into how HSV gB may 
function. As previously mentioned it shares structural features with both class I and class 
II fusion proteins. In chapters III and IV, I focused on the gB fusion loops, a feature with 
similarities in the class II proteins. Next, we turned our attention to those features 
reminiscent of class I fusion proteins, the a-helical core and the globular crown. 
The three major structural hallmarks of class I fusion proteins are the globular 
crown, the long central a-helix, and the fusion peptide. All class I fusion proteins are 
trimeric spikes with globular heads at the viral membrane distal head. This region is 
usually where the receptor binding domain is located. HIV gP 120 forms the globular 
head of the env protein. All of the receptor and co-receptor binding functions reside in 
this subunit. In influenza HA and the SARS spike protein, receptor interactions occur 
thru a domain at the top of the crown. Where more detailed structural data is available, 
the residues that directly contact the receptors are often in loops. Coincidentally, the gB 
crown has many large loops that along with a series of P-sheets form the globular crown 
domain. 
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I chose to mutate the crown of gB (domain IV) for several reasons. Firstly, as 
mentioned above, the globular crown is where the receptor binding domain resides in 
class I fusion proteins. Although as mentioned previously, gB is a class III protein. 
Secondly, our laboratory generated and characterized a group of mAbs represented by 
SS10 whose epitopes map to this region (Fig. IOC). They have strong neutralizing 
activity against virus and block gB binding to cells. Thirdly, peptides generated from gB 
sequences in this region block infection. Taken together, I suspected that these data 
suggest that a gB receptor binding domain is located in the crown (boxed in Fig. 26A). 
During the structural transition of a class I fusion protein from pre- to post-fusion, 
the central a-helix serves as a structural anchor, remaining largely unchanged while 
rearrangements occur around it. The post-fusion 6HB forms when another a-helical 
domain packs into the grooves of coiled coil formed by the 3fold axis of the central <x-
helix. Mutations in this region have been shown to affect function, possibly by changing 
the stability of the post-fusion 6HB bundle. For these reasons, I chose to target this 
structural feature of gB as well. 
RESULTS 
Selection of Target Residues 
The target residues discussed in this chapter were chosen by three different 
methods. Prior to this project, little mutagenic analysis had been carried out on gB 
because most of the generated mutants were misfolded. However, changes at the protein 
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Figure 26. gB Crown was target for mutagenesis. I hypothesized that 
the gB domain IV crown has a role in receptor binding, thus multiple 
targets were chosen for mutagenesis by three methods. A) Ribbon 
diagram of gB protomer colored by secondary structure succession. B) 
Ten charged residues in the loops and five residues in a bulky charged 
pocket were mutated. C) Two mutations based on roe determinants from 
previously identified virus strains were made. 
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level have been sequenced from various viral isolates that displayed significantly 
different phenotypes from WT virus. I reasoned that since the viruses with these 
mutations were infectious and naturally occurring, gB was likely to tolerate such 
mutations. 
Two rate-of- entry (roe) determinants mapped to the crown of gB (Fig. 26B). The 
mutation of a conserved G at position 594 to R confers a slow roe phenotype. This 
mutation was isolated from the tsB5 MAR generated by the Glorioso lab. Similarly, the 
mutation of a V at position 553 to A conferred a fast roe phenotype to virus. 
Interestingly, this mutation also confers increased neuroinvasiness and is one of several 
mutations gB needed for a syncytial phenotype. To further explore the role extended 
non-polar side chains may have in the function of this residue, V553 was also mutated to 
leucine. 
gB V553 is located in the small a-helix adjacent to the viral distal portion of the 
central a-helix. In addition to this mutation in the core, I generated two additional 
mutants in this domain. From each, a single turn of the central a-helix has been removed 
by deleted four amino acids. The residues deleted were a.a. 501-504, and a.a.536-539 and 
the mutants are named A501-504 and A536-539. Similarly, a turn of an a-helix in 
domain II was deleted. Residues a.a. 460-463 were deleted and this mutant is named 
A460-463. It must be noted that a.a .460-463 is not included in the HSV gB-1 crystal 
structure. 
I targeted the globular structures of the gB crown (domain IV) by two methods 
(Fig. 26C). Published data suggests that conserved tryptophans and tyrosines on the 
surface of a protein are often sites of protein-protein interaction. Hoping to identify one 
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of these so called "hot-spots," a pocket formed by bulky residues (R638, Y640, Y647, 
Y649, H657) was chosen for mutagenesis. Several mutants targeting this pocket were 
generated: R638A, Y640A, Y640I, F641Y, Y647A, Y649A, H657A, H657R. Lastly, 
ligand-receptor contacts are often mediated by residues in loops. To target the extensive 
loops that make up the crown, charged residues in domain IV loops were mutated to 
alanines. D566A, Q584A, N585A, R588A, R592A, R605A, E607A, D608A, and Q609A 
were all generated. 
Only One Mutant (Q584A) is Impaired in Cell-cell Fusion 
All mutants were tested for function using the quantitative luciferase based cell-
cell fusion assay described previously. As before, the fusion activity of the mutants is 
expressed as a percentage of fusion facilitated by WT gB, and we consider that mutants 
exhibiting fusion activity below 20% were non-functional, and those between 20% and 
51% were significantly impaired. Mutations to one residue, H657 improved gB function 
in cell-cell fusion (Fig. 27A). H657A and H657R, function at 116% and 130% of WT 
levels, respectively. In addition, H657R was expressed on the surface at 148% of WT 
levels. Only one mutant (of 24) was significantly impaired in fusion. Q584A functions 
at 49% of WT gB levels. This mutant was the most consistent performer out of the entire 
panel. After being tested eight times, the standard deviation for this mutant was only 
3.4%. The nine remaining mutants were unremarkable. They all functioned at 75% of 
WT levels or better. 
11 of 24 mutants failed to be expressed on the surface of CHO cells. These 
mutants: D566A, R588A, R592A, R605A, R638A, Y640A, Y640I, Y647A, A460-463, 
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A Fusion Activity of gB Crown Mutants 
B Surface Expression of gB Crown Mutants 
t 200 
Figure 27. Cell-cell fusion activity and surface expression of gB mutants 
in CHO cells. A) Luciferase fusion assay, also see figs 15 or 17. B) Cell-
based ELISA (CELISA) was used as a measure of cell-surface expression of 
gB mutant proteins in CHO cells. Based on CELISA data not shown, D566A, 
R588A, R592A, R605A, R638A, Y640A, Y640I, Y647A all failed to be 
expressed in the cell surface, thus I concluded that they had defects in 
processing. 
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A501-504, and A536-539 were deemed misfolded and disregarded for future 
characterization. 11 of the 12 remaining mutants were expressed on the cell surface at 
WT levels (Fig. 27B). Y649A was expressed on the surface at 41 % of WT and 
functioned at 61% of WT levels. However, when the protein was expressed at 32° C, it 
was expressed and functioned at WT levels. The roe mutations, G594R and V553A, both 
functioned at about 70% of WT levels. Interestingly, by substituting V553 to leucine, 
function was restored to WT. 
These results suggest that of all the amino acids targeted, only Q584 and perhaps 
H657, have roles in gB function. In addition, because substitutions to alanine (or 
isoleucine for Y640) yielded misfolded proteins, I conclude that D566, R588, R592, 
R605, R638, Y640, Y647 and a-helices have important roles in either gB folding or 
structure. Also, the increased surface expression of H657R is curious, but we have little 
idea what this means for the role of this residue in gB function or folding. 
Q584A is Conformationally Correct 
Because Q584A was the only significantly impaired mutant protein, I needed to 
verify that it was properly folded. To achieve this goal, I immunoprecipitated transfected 
cell extracts with mAbs (DL16, SS55, and SS145) that recognize conformation 
dependent epitopes, as previously described in chapter III (Fig. IOC). Q584A was 
immunoprecipitated from lysates of transfected 293T cells. It was recognized by all three 
a-gB mAbs and was not recognized by the a-cmyc (data not shown). 
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Complementation ofHSVgB Null Virus with gB Crown Mutants 
HSV glycoprotein mediated cell-cell fusion is used as a surrogate for virus-cell 
fusion. Another way to test the function of gB mutant proteins is to incorporate them into 
an HSV strain lacking the gB genes and test the ability of the complemented viruses to 
enter cells. Thus, I characterized the gB crown mutants using a complementation assay 
previously described in chapter IV. All data were normalized to the entry (virus titer) of 
virus complemented with WT gB and expressed as % WT entry. 
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Figure 28. Ability of fusion loop mutants to complement entry of a gB 
null HSV virus. Vero cells were transfected with plasmids encoding gB 
mutants, incubated overnight, and infected with gB-null HSV that had been 
phenotypically complemented with wild-type gB to allow for entry. Cell lysates 
containing progeny virions complemented with the gB mutants were harvested 
and assayed for virus entry into gB expressing VB38 cells. After 2 days of 
incubation at 37°C, cells were stained and plaques were counted. Titers are 
expressed as % of PFU/ml of virus complemented by WT gB. The data and 
standard deviations errors were derived from a minimum of three experiments 
and the figure represents a compilation of all the data. 
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When the titer for a particular mutant virus was 10% of WT or less, we 
considered it to be severely impaired for virus entry. Thus, none of the crown mutants 
were severely impaired for entry. Four (V553A, Q584A, G594R, and F641Y) mutants 
functioned for entry into cells between 10 and 40% of WT levels (Fig. 29). Clearly, 
mutations at these positions impair gB function. Mutations at H657, in the bulky pocket 
of the crown, yielded interesting results. H657A and H657R functioned in virus entry at 
60% and 125% of WT, respectively. It should be noted that F641 is also located in this 
pocket and V553A and G594R are the roe mutants. In addition, Q584A was impaired in 
cell-cell fusion. 
Secreted gB Mutants were Produced 
In chapter IV, I described functional assays that were used to examine possible 
mechanisms for fusion inhibition by several gB mutants. The mutants were expressed as 
truncated, secreted proteins using a baculovirus expression system and were examined for 
their ability to insert into target membranes, block virus entry, bind cells, and interact 
with gH/gL. To examine a mutation in the crown using these assays, a secreted truncated 
gB730t-Q584A was produced (Fig. 29). 
The purified protein was tested for proper folding by immunoprecipitation using 
mAbs against conformation dependent epitopes. In addition to DL16, we utilized three 
mAbs: SS10, SS145, and C226, all described previously (Fig. IOC). WT gB730 and 
Q584A were recognized by each of the four a-gB mAbs (Fig. 29). The a c-myc control 
antibody recognized neither. These data suggest that the secreted mutant proteins are 
antigenically correct at four distinct epitopes. 
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Q584A is Not Impaired in Liposome Binding 
Mutations to key residues in the fusion loops impaired liposome association. 
Liposome association can occur through superficial electrostatic interactions or through 
more stable interactions typical of proteins hydrophobically anchored into the membrane 
(44). Above, we showed soluble gB stably binds liposomes and that mutations to the 
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Figure 29. gB-730t-Q584A is expressed in baculovirus system are expressed and 
folded correctly. (A) Q584A was cloned and expressed in a baculovirus expression 
system as secreted a form truncated after amino acid 730. Proteins were visualized by 
silver stain and B) detected with R69 and visualized by western blot. (C) The gB mutant 
proteins were immunoprecipitated using MAbs DL16 (lanes A), SS10 (lanes B), SS55 
(lanes C), or C226 (laneD) against conformational epitopes. Anti c-Myc was used as a 
negative control (lanes D). gB mutations are indicated at the top of each Western blot. 
WT gB was expressed from pPEP98. PAb R69 was used for detection of gB. Molecular 
weight markers are indicated on the left in kd. 
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fusion loops abrogate this function, thus I hypothesize that mutations to the crown should 
not impair liposome association. 
gB Q584A was tested for liposome association using the liposome floatation 
assay described above. Soluble gB Q584A and WT gB730 were incubated with 
liposomes at 37°, pH 7.4 for 1 hour. The mixture was then adjusted to 1M KCL and 
incubated at 37° for an additional 15 mins. They were then layered beneath a 5% to 40% 
discontinuous sucrose gradient and centrifuged. Most of the fluorescent liposomes 
floated to the top of the gradient (Fig. 21 A). I used ELISA to quantify gB in each 
fraction, using mAb SS145 (binds domain IV, Fig. IOC) to capture gB and pAb R69 for 
detection. 
As we expected, WT gB associates with liposomes (Fig. 30). Approximately 
40% was located in fraction 1, a small portion is located in the middle fractions, and 
about 50% is located in fraction 7. Q584A was found in the same fractions as WT gB. 
Y179S is shown as a negative control, all of the protein was located in fraction 7. 
Slightly less Q584A was found in fraction 1 compared to WT, this may be due to small 
differences in the input amount. However, I conclude that Q584A floats like WT gB. 
This suggest that Q584 has no role in membrane insertion. 
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Figure 30. Mutations in the gB crown have no effect on liposome binding. WT 
gB730t, gB730t-Q584A , and gB730t-Y179S (- control) were incubated with unlabeled 
liposomes for 1 hr at 37 °C, adjusted to 1M KCL and incubated at 37 °C for an 
additional 15 mins and layered beneath a discontinuous 5 - 40% sucrose gradient. 
Gradients were fractionated and adjusted to . 1 % NP40. Only fractions 1, 4, and 7 are 
shown. Samples were analyzed in duplicate by capture ELISA using SS145 to 
capture gB and R69 to detect it. 
Mutant gB Proteins Engage the Unknown gB Receptor Like WT 
Dr. Florent Bender, in our lab, previously showed that gB730t blocks HSV entry 
into Gro2C cells (8), we suggest that this function is indicative of binding an unknown 
receptor. In chapter IV, I hypothesized that the fusion loops had no role in receptor 
binding and suggested that this function may reside in the crown. 
To test this in a blocking assay, I plated Gro2C cells in a 96-well plate at 80% 
confluency. Decreasing equimolar concentrations of WT or mutant gB were added for 30 
min at 4° C. HSV-1 tkl2, which expresses (3-gal under the immediate early promoter, 
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was added at an MOI of 10 for lh at 4° C. The virus-cell mixture was shifted to 37° C, 
incubated for 6h, and infection was quantified by P-galactosidase expression. 
I observed that gB730t-Q584A blocked entry as well as WT gB (Fig. 31 A). 5 uM 
WT gB or mutant gB was sufficient to inhibit entry between 70% and 90%. In one 
repetition, Q584A blocked entry much better than WT. However, this result was not 
reproducible. It is possible that a contaminant or gB aggregate was in this aliquot of 
Q584A. This result should be explored further. This data suggests that Q584A is not 
impaired in receptor binding. We hypothesized that a receptor binding domain is located 
in the crown region. Based on our data we must conclude that we have either not mutated 
a residue involved in this function or that the region is located elsewhere in gB. 
Mutant gB Proteins are Impaired in Cell Binding 
Thus far, I have shown that Q584A-730t is WT for liposome association and for 
blocking of virus entry. Next, I tested the ability of the gB mutant protein to bind Gro2C 
cells. I suspected that gB730t-Q584A would be impaired in cell binding because Q584A 
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Figure 31. gB730t-Q584A blocks entry and binds cells like WT gB. (A) Soluble 
WT and mutant gB proteins inhibit HSV into Gro2C cells. Decreasing equimolar 
concentrations of gB proteins were incubated with cells in an ELISA plate for 1 h at 
4°C. HSV was then added to cells at an MOI of 10 and allowed to attach for 30 min, 
after which the temperature was raised to 37° C and incubation continued for 6 h. 
Cells were lysed with 0 .5% NP-40 and p-galactosidase activity was assayed. Error 
bars are standard deviation. (B) WT gB730t and gB730t-Q584A was tested for 
binding to Gro2C cells by cELISA in parallel to (A). Decreasing equimolar 
concentrations of gB was added to cells in an ELISA plate for 1h at 4°C. Wells were 
washed with PBS and fixed with 3% paraformaldehyde. cELISA was used to detect 
cell bound gB using R69 to detect the protein. 
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only functions at 46% of WT levels and thus far was not impaired in any of the functional 
assays. mAbs (SS55 and SS10) which represent two distinct functional regions block 
binding of WT gB730t to cells (7, 8). SS55 binds domain I near the fusion loops. In 
chapter IV, I showed they have a role in cell binding. Because SS10 binds residues in the 
crown, I suspected that the crown has a role in cell binding and anticipated Q584 is 
important in this function. 
Decreasing equimolar concentrations of WT g or mutant gB were added to 
monolayers of Gro2C cells for lh at 4° C, washed, and fixed in 3% PFA for 10 min. 
Cell-based ELISA was used to detect gB binding. Q584A binds Gro2C cells like WT 
(Fig. 3IB). Thus, its defect in fusion is not due to insufficiencies in target membrane 
insertion, receptor binding, or cell binding. Suprisingly, Q584A binds Gro2C cells like 
WT. Thus, its defect in fusion is not due to insufficiencies in target membrane insertion, 
receptor binding, or cell binding. 
Heterologous Interactions ofgB Fusion Loop Mutants with gH/gL 
In collaboration with Dr. Atanasiu, in our lab, we used bimolecular 
complementation (BiMC) to examine the ability of gB fusion loop mutants to interact 
with gH/gL in a fusogenic environment. Previously, we used BiMC to show that gB 
interacts with gH/gL in receptor bearing cells when gD is added in trans as a soluble 
protein (gD306). This interaction occurred concurrently with cell-cell fusion (2). If 
gD306 was omitted, there was no interaction between the tagged forms of gB and gH/gL 
and no fusion. Perhaps my gB fusion loops mutants failed to function in fusion because 
they could no longer interact with gD or gH/gL. Here, to test this notion we asked 
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whether a mutation to the gB crown (Q584A) alters the interaction between gH/gL that 
occurs in response to gD/ receptor binding. 
Here, to test this notion, we asked whether a mutation to the gB crown alters the 
interaction between gH/gL and gB that occurs in response to gD/ receptor binding. For 
this purpose Dr. Atanasiu tagged the full-length mutant gB proteins, Q584A and Y179S 
(as a negative control) at the C-terminus C-terminal half of EYFP (Venus) to create 
Be*584 and, Be*179. CIO cells were transfected with Hn, gL and Be (WT or mutants). At 
20 h post-transfection, fusion was triggered by the addition of soluble gD306. Cells were 
examined by confocal microscopy for restoration of EYFP fluorescence in the green 
channel; glycoprotein expression was monitored in the red channel by using R137 gH 
Pab (Fig. 23) or A22+SS55 gB Mab (not shown). 
In chapter IV, we showed that no fusion occurred and no interaction was observed 
when WT Venus tagged gB was replaced by any one of the fusion loop mutants. In 
contrast, when WT venus tagged gB was replaced with Q584A gB, fusion and an 
interaction between gB and gH/gL occurred (Fig. 32). When WT venus tagged gB was 
replaced with the negative control (Y179S), no syncytia were observed and only 
background green was observed. Thus, it is unlikely that Q584A is impaired in 
heterologous interaction with gH/gL. 
In closing, I hypothesized that the gB domain IV crown has a role in receptor 
binding. Many mutations were made, including several charged residues in the loops of 
the crown. By cell-cell fusion and complementation, I have shown that Q584 and 
perhaps H657 are important in fusion. gB730t-Q584A was produced and characterized 
for cell binding, blocking of virus entry, liposome flotation, and gH/gL binding. 
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Figure 32. Full-length Q584A Interacts with gH/gL by BiMC. When 
fusion was triggered by the addition of gD306 to cells transfected with gl_, Hn 
and WT Be, green syncytia formed (top panel). When Be was substituted 
with a crown mutant (Bc*584) syncytia formed and green fluorescence was 
observed (middle panels). When Be was substituted with a fusion loop 
mutant negative control (Bc*179) no syncytia was observed and only 
background green was observed. C10 cells were transfected with Hn, WT Be 
or the indicated mutant Be for 20 h, fixed, and stained with the anti-gHpAb 
R137. All were analyzed by immunofluorescent assay for protein (red) and 
YFP (green). Confocal images were captured at 100X magnification and all 
images were captured by using the same camera setting. 
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Unexpectedly, the mutant protein behaved like WT gB730t in all of these assays. There 
was one instance where gB730t-Q584A blocked virus entry much better than WT. This 
result would support my hypothesis and be a possible mechanism of fusion inhibition by 
Q584A. But for unknown reasons, this result could not be repeated. I strongly urge that 
gB730t-Q584A be remade and gB730t-H263R be generated and characterized using 
these methods to explore their role in receptor engagement/release and cell binding. 
ADDITIONAL EXPERIMENTS 
mAb Modulation ofgB Liposome Association 
We hypothesized that a-gB monoclonal antibodies could inhibit liposome binding 
if they bound near a domain directly involved in this interaction. Using a modification of 
liposome floatation assay, I incubated gB730t with SS10, SS55, or A22 for 30 min at 37° 
C. Then liposomes were added and the mixture was incubated at 37° C for an additional 
30 mins. The mixture was then subjected to overlay with sucrose, subjected to 
centrifugation, fractionated, and gB was quantitated as described in chapter IV. Values 
are quantitated as % the no liposome negative control, fraction 7. This was expected to 
have been the maximum signal. 
As expected without any mAb approximately 60% of gB was located in fraction 1 
(top), and without liposomes all gB was located in fraction 7 (bottom) (Fig. 33). When 
gB was incubated with SS10, gB was located in fractions 1 and 7 just as with the no mAb 
control. However, the overall signal was much greater. When gB was incubated with 
SS55, the vast majority was located in fraction 7. When gB was incubated with A22 and 
C226, the majority of gB was located in fraction 1 and very little was in the fraction 7. 
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Antibody Modulation of gB Liposome Floatation 
• Fraction 1 
H Fraction 4 
B Fraction 7 
nomAb 
Figure 33. mAb Modulation of gB Liposome Association. 
gB730t was incubated with mAbs for 30 mins before addition to 
liposomes and further incubation (see Fig. 21). Values are 
calculated as % of what should have been the maximum signal (no 
liposomes, fraction 7), because the overall signal per gradient was 
different based on antibody used in per-incubation. 
However, the overall signal was much lower. These results suggest that of the three 
mAbs tested, only SS55 blocks gB liposome interaction. Interestingly, the SS55 epitope 
includes a portion of domain I, near the fusion loops, and a portion of domain V. 
However, this assay is technically complex because the overall signal seemed to change 
based on the mAb used for incubation with gB. When incubated with SS10, there was a 
much higher overall signal than in the no mAb control. When incubated with A22 there 
was a much lower signal than in the no mAb control. Interestingly, both SS10 and A22 
recognize a gB epitope in domain IV. Thus, it is difficult to explain why the gB signal 
increases and decreases when incubated with different mAbs. 
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